fbpx
Wikipedia

Cardiovascular disease

November 27, 2023

"Heart condition" redirects here. For other uses, see Heart condition (disambiguation).

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels.[3] CVDs constitute a class of diseases that includes: coronary artery diseases (e.g. angina, heart attack), heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.[3][4]

Cardiovascular disease
Micrograph of a heart with fibrosis (yellow) and amyloidosis (brown). Movat's stain.
SpecialtyCardiology
SymptomsChest pain, shortness of breath, fatigue, loss of consciousness
ComplicationsHeart failure, heart attack, stroke, aneurysm, peripheral artery disease, sudden cardiac arrest.[1]
Usual onsetOlder adults[2]
TypesCoronary artery diseases, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy,[3][4] Arrhythmia
Risk factorsDiabetes,[3] high blood lipids, excess weight, Smoking, excessive drug use, and excessive alcohol intake
PreventionHealthy eating, exercise, avoiding tobacco smoke, limited alcohol intake,[3] Overall lifestyle changes
TreatmentTreating high blood pressure, high blood lipids, diabetes[3]
MedicationAspirin, beta blockers, blood thinners
Deaths17.9 million / 32% (2015)[5]

The underlying mechanisms vary depending on the disease.[3] It is estimated that dietary risk factors are associated with 53% of CVD deaths.[6] Coronary artery disease, stroke, and peripheral artery disease involve atherosclerosis.[3] This may be caused by high blood pressure, smoking, diabetes mellitus, lack of exercise, obesity, high blood cholesterol, poor diet, excessive alcohol consumption,[3] and poor sleep,[7][8] among other things. High blood pressure is estimated to account for approximately 13% of CVD deaths, while tobacco accounts for 9%, diabetes 6%, lack of exercise 6%, and obesity 5%.[3] Rheumatic heart disease may follow untreated strep throat.[3]

It is estimated that up to 90% of CVD may be preventable.[9][10] Prevention of CVD involves improving risk factors through: healthy eating, exercise, avoidance of tobacco smoke and limiting alcohol intake.[3] Treating risk factors, such as high blood pressure, blood lipids and diabetes is also beneficial.[3] Treating people who have strep throat with antibiotics can decrease the risk of rheumatic heart disease.[11] The use of aspirin in people who are otherwise healthy is of unclear benefit.[12][13]

Cardiovascular diseases are the leading cause of death worldwide except Africa.[3] Together CVD resulted in 17.9 million deaths (32.1%) in 2015, up from 12.3 million (25.8%) in 1990.[5][4] Deaths, at a given age, from CVD are more common and have been increasing in much of the developing world, while rates have declined in most of the developed world since the 1970s.[14][15] Coronary artery disease and stroke account for 80% of CVD deaths in males and 75% of CVD deaths in females.[3] Most cardiovascular disease affects older adults. In the United States 11% of people between 20 and 40 have CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD.[2] The average age of death from coronary artery disease in the developed world is around 80, while it is around 68 in the developing world.[14] CVD is typically diagnosed seven to ten years earlier in men than in women.[3]: 48 

Types

 
Disability-adjusted life year for inflammatory heart diseases per 100,000 inhabitants in 2004[16]
  No data
  Less than 70
  70–140
  140–210
  210–280
  280–350
  350–420
  420–490
  490–560
  560–630
  630–700
  700–770
  More than 770

There are many cardiovascular diseases involving the blood vessels. They are known as vascular diseases.[citation needed]

There are also many cardiovascular diseases that involve the heart.

Risk factors

There are many risk factors for heart diseases: age, sex, tobacco use, physical inactivity, non-alcoholic fatty liver disease, excessive alcohol consumption, unhealthy diet, obesity, genetic predisposition and family history of cardiovascular disease, raised blood pressure (hypertension), raised blood sugar (diabetes mellitus), raised blood cholesterol (hyperlipidemia), undiagnosed celiac disease, psychosocial factors, poverty and low educational status, air pollution, and poor sleep.[3][17][18][19][20][21] While the individual contribution of each risk factor varies between different communities or ethnic groups the overall contribution of these risk factors is very consistent.[22] Some of these risk factors, such as age, sex or family history/genetic predisposition, are immutable; however, many important cardiovascular risk factors are modifiable by lifestyle change, social change, drug treatment (for example prevention of hypertension, hyperlipidemia, and diabetes).[23] People with obesity are at increased risk of atherosclerosis of the coronary arteries.[24]

Genetics

Cardiovascular disease in a person's parents increases their risk by ~3 fold,[25] and genetics is an important risk factor for cardiovascular diseases. Genetic cardiovascular disease can occur either as a consequence of single variant (Mendelian) or polygenic influences.[26] There are more than 40 inherited cardiovascular disease that can be traced to a single disease-causing DNA variant, although these conditions are rare.[26] Most common cardiovascular diseases are non-Mendelian and are thought to be due to hundreds or thousands of genetic variants (known as single nucleotide polymorphisms), each associated with a small effect.[27][28]

Age

 
Calcified heart of an older woman with cardiomegaly

Age is the most important risk factor in developing cardiovascular or heart diseases, with approximately a tripling of risk with each decade of life.[29] Coronary fatty streaks can begin to form in adolescence.[30] It is estimated that 82 percent of people who die of coronary heart disease are 65 and older.[31] Simultaneously, the risk of stroke doubles every decade after age 55.[32]

Multiple explanations are proposed to explain why age increases the risk of cardiovascular/heart diseases. One of them relates to serum cholesterol level.[33] In most populations, the serum total cholesterol level increases as age increases. In men, this increase levels off around age 45 to 50 years. In women, the increase continues sharply until age 60 to 65 years.[33]

Aging is also associated with changes in the mechanical and structural properties of the vascular wall, which leads to the loss of arterial elasticity and reduced arterial compliance and may subsequently lead to coronary artery disease.[34]

Sex

See also: Cardiovascular disease in women

Men are at greater risk of heart disease than pre-menopausal women.[29][35] Once past menopause, it has been argued that a woman's risk is similar to a man's[35] although more recent data from the WHO and UN disputes this.[29] If a female has diabetes, she is more likely to develop heart disease than a male with diabetes.[36] Women who have high blood pressure and had complications in their pregnancy have three times the risk of developing cardiovascular disease compared to women with normal blood pressure who had no complications in pregnancy.[37][38]

Coronary heart diseases are 2 to 5 times more common among middle-aged men than women.[33] In a study done by the World Health Organization, sex contributes to approximately 40% of the variation in sex ratios of coronary heart disease mortality.[39] Another study reports similar results finding that sex differences explains nearly half the risk associated with cardiovascular diseases[33] One of the proposed explanations for sex differences in cardiovascular diseases is hormonal difference.[33] Among women, estrogen is the predominant sex hormone. Estrogen may have protective effects on glucose metabolism and hemostatic system, and may have direct effect in improving endothelial cell function.[33] The production of estrogen decreases after menopause, and this may change the female lipid metabolism toward a more atherogenic form by decreasing the HDL cholesterol level while increasing LDL and total cholesterol levels.[33]

Among men and women, there are differences in body weight, height, body fat distribution, heart rate, stroke volume, and arterial compliance.[34] In the very elderly, age-related large artery pulsatility and stiffness are more pronounced among women than men.[34] This may be caused by the women's smaller body size and arterial dimensions which are independent of menopause.[34]

Tobacco

Cigarettes are the major form of smoked tobacco.[3] Risks to health from tobacco use result not only from direct consumption of tobacco, but also from exposure to second-hand smoke.[3] Approximately 10% of cardiovascular disease is attributed to smoking;[3] however, people who quit smoking by age 30 have almost as low a risk of death as never smokers.[40]

Physical inactivity

Further information: Sedentary lifestyle

Insufficient physical activity (defined as less than 5 x 30 minutes of moderate activity per week, or less than 3 x 20 minutes of vigorous activity per week) is currently the fourth leading risk factor for mortality worldwide.[3] In 2008, 31.3% of adults aged 15 or older (28.2% men and 34.4% women) were insufficiently physically active.[3] The risk of ischemic heart disease and diabetes mellitus is reduced by almost a third in adults who participate in 150 minutes of moderate physical activity each week (or equivalent).[41] In addition, physical activity assists weight loss and improves blood glucose control, blood pressure, lipid profile and insulin sensitivity. These effects may, at least in part, explain its cardiovascular benefits.[3]

Diet

Further information: Saturated fat § Cardiovascular disease, Salt and cardiovascular disease, and Lipid hypothesis

High dietary intakes of saturated fat, trans-fats and salt, and low intake of fruits, vegetables and fish are linked to cardiovascular risk, although whether all these associations indicate causes is disputed. The World Health Organization attributes approximately 1.7 million deaths worldwide to low fruit and vegetable consumption.[3] Frequent consumption of high-energy foods, such as processed foods that are high in fats and sugars, promotes obesity and may increase cardiovascular risk.[3] The amount of dietary salt consumed may also be an important determinant of blood pressure levels and overall cardiovascular risk.[3] There is moderate quality evidence that reducing saturated fat intake for at least two years reduces the risk of cardiovascular disease.[42] High trans-fat intake has adverse effects on blood lipids and circulating inflammatory markers,[43] and elimination of trans-fat from diets has been widely advocated.[44][45] In 2018 the World Health Organization estimated that trans fats were the cause of more than half a million deaths per year.[45] There is evidence that higher consumption of sugar is associated with higher blood pressure and unfavorable blood lipids,[46] and sugar intake also increases the risk of diabetes mellitus.[47] High consumption of processed meats is associated with an increased risk of cardiovascular disease, possibly in part due to increased dietary salt intake.[19]

Alcohol

Further information: Alcohol and cardiovascular disease

The relationship between alcohol consumption and cardiovascular disease is complex, and may depend on the amount of alcohol consumed.[48] There is a direct relationship between high levels of drinking alcohol and cardiovascular disease.[3] Drinking at low levels without episodes of heavy drinking may be associated with a reduced risk of cardiovascular disease,[49] but there is evidence that associations between moderate alcohol consumption and protection from stroke are non-causal.[50] At the population level, the health risks of drinking alcohol exceed any potential benefits.[3][51]

Celiac disease

Untreated celiac disease can cause the development of many types of cardiovascular diseases, most of which improve or resolve with a gluten-free diet and intestinal healing. However, delays in recognition and diagnosis of celiac disease can cause irreversible heart damage.[20]

Sleep

A lack of good sleep, in amount or quality, is documented as increasing cardiovascular risk in both adults and teens. Recommendations suggest that Infants typically need 12 or more hours of sleep per day, adolescent at least eight or nine hours, and adults seven or eight. About one-third of adult Americans get less than the recommended seven hours of sleep per night, and in a study of teenagers, just 2.2 percent of those studied got enough sleep, many of whom did not get good quality sleep. Studies have shown that short sleepers getting less than seven hours sleep per night have a 10 percent to 30 percent higher risk of cardiovascular disease.[7][52]

Sleep disorders such as sleep-disordered breathing and insomnia, are also associated with a higher cardiometabolic risk.[53] An estimated 50 to 70 million Americans have insomnia, sleep apnea or other chronic sleep disorders.[citation needed]

In addition, sleep research displays differences in race and class. Short sleep and poor sleep tend to be more frequently reported in ethnic minorities than in whites. African-Americans report experiencing short durations of sleep five times more often than whites, possibly as a result of social and environmental factors. Black children and children living in disadvantaged neighborhoods have much higher rates of sleep apnea.[8]

Socioeconomic disadvantage

Cardiovascular disease affects low- and middle-income countries even more than high-income countries.[54] There is relatively little information regarding social patterns of cardiovascular disease within low- and middle-income countries,[54] but within high-income countries low income and low educational status are consistently associated with greater risk of cardiovascular disease.[55] Policies that have resulted in increased socio-economic inequalities have been associated with greater subsequent socio-economic differences in cardiovascular disease[54] implying a cause and effect relationship. Psychosocial factors, environmental exposures, health behaviours, and health-care access and quality contribute to socio-economic differentials in cardiovascular disease.[56] The Commission on Social Determinants of Health recommended that more equal distributions of power, wealth, education, housing, environmental factors, nutrition, and health care were needed to address inequalities in cardiovascular disease and non-communicable diseases.[57]

Air pollution

Particulate matter has been studied for its short- and long-term exposure effects on cardiovascular disease. Currently, airborne particles under 2.5 micrometers in diameter (PM2.5) are the major focus, in which gradients are used to determine CVD risk. Overall, long-term PM exposure increased rate of atherosclerosis and inflammation. In regards to short-term exposure (2 hours), every 25 μg/m3 of PM2.5 resulted in a 48% increase of CVD mortality risk.[58] In addition, after only 5 days of exposure, a rise in systolic (2.8 mmHg) and diastolic (2.7 mmHg) blood pressure occurred for every 10.5 μg/m3 of PM2.5.[58] Other research has implicated PM2.5 in irregular heart rhythm, reduced heart rate variability (decreased vagal tone), and most notably heart failure.[58][59] PM2.5 is also linked to carotid artery thickening and increased risk of acute myocardial infarction.[58][59]

Cardiovascular risk assessment

Existing cardiovascular disease or a previous cardiovascular event, such as a heart attack or stroke, is the strongest predictor of a future cardiovascular event.[60] Age, sex, smoking, blood pressure, blood lipids and diabetes are important predictors of future cardiovascular disease in people who are not known to have cardiovascular disease.[61] These measures, and sometimes others, may be combined into composite risk scores to estimate an individual's future risk of cardiovascular disease.[60] Numerous risk scores exist although their respective merits are debated.[62] Other diagnostic tests and biomarkers remain under evaluation but currently these lack clear-cut evidence to support their routine use. They include family history, coronary artery calcification score, high sensitivity C-reactive protein (hs-CRP), ankle–brachial pressure index, lipoprotein subclasses and particle concentration, lipoprotein(a), apolipoproteins A-I and B, fibrinogen, white blood cell count, homocysteine, N-terminal pro B-type natriuretic peptide (NT-proBNP), and markers of kidney function.[63][64] High blood phosphorus is also linked to an increased risk.[65]

Depression and traumatic stress

There is evidence that mental health problems, in particular depression and traumatic stress, is linked to cardiovascular diseases. Whereas mental health problems are known to be associated with risk factors for cardiovascular diseases such as smoking, poor diet, and a sedentary lifestyle, these factors alone do not explain the increased risk of cardiovascular diseases seen in depression, stress, and anxiety.[66] Moreover, posttraumatic stress disorder is independently associated with increased risk for incident coronary heart disease, even after adjusting for depression and other covariates.[67]

Occupational exposure

Main article: Occupational cardiovascular disease

Little is known about the relationship between work and cardiovascular disease, but links have been established between certain toxins, extreme heat and cold, exposure to tobacco smoke, and mental health concerns such as stress and depression.[68]

Non-chemical risk factors

A 2015 SBU-report looking at non-chemical factors found an association for those:[69]

  • with mentally stressful work with a lack of control over their working situation — with an effort-reward imbalance[69]
  • who experience low social support at work; who experience injustice or experience insufficient opportunities for personal development; or those who experience job insecurity[69]
  • those who work night schedules; or have long working weeks[69]
  • those who are exposed to noise[69]

Specifically the risk of stroke was also increased by exposure to ionizing radiation.[69] Hypertension develops more often in those who experience job strain and who have shift-work.[69] Differences between women and men in risk are small, however men risk having and dying of heart attacks or stroke twice as often as women during working life.[69]

Chemical risk factors

A 2017 SBU report found evidence that workplace exposure to silica dust, engine exhaust or welding fumes is associated with heart disease.[70] Associations also exist for exposure to arsenic, benzopyrenes, lead, dynamite, carbon disulphide, carbon monoxide, metalworking fluids and occupational exposure to tobacco smoke.[70] Working with the electrolytic production of aluminium or the production of paper when the sulphate pulping process is used is associated with heart disease.[70] An association was also found between heart disease and exposure to compounds which are no longer permitted in certain work environments, such as phenoxy acids containing TCDD(dioxin) or asbestos.[70]

Workplace exposure to silica dust or asbestos is also associated with pulmonary heart disease. There is evidence that workplace exposure to lead, carbon disulphide, phenoxyacids containing TCDD, as well as working in an environment where aluminum is being electrolytically produced, is associated with stroke.[70]

Somatic mutations

As of 2017, evidence suggests that certain leukemia-associated mutations in blood cells may also lead to increased risk of cardiovascular disease. Several large-scale research projects looking at human genetic data have found a robust link between the presence of these mutations, a condition known as clonal hematopoiesis, and cardiovascular disease-related incidents and mortality.[71]

Radiation therapy

Radiation treatments (RT) for cancer can increase the risk of heart disease and death, as observed in breast cancer therapy.[72] Therapeutic radiation increases the risk of a subsequent heart attack or stroke by 1.5 to 4 times;[73] the increase depends on the dose strength, volume, and location. Use of concomitant chemotherapy, e.g. anthracyclines, is an aggravating risk factor.[74] The occurrence rate of RT induced cardiovascular disease is estimated between 10% and 30%.[74]

Side-effects from radiation therapy for cardiovascular diseases have been termed radiation-induced heart disease or radiation-induced cardiovascular disease.[75][76] Symptoms are dose-dependent and include cardiomyopathy, myocardial fibrosis, valvular heart disease, coronary artery disease, heart arrhythmia and peripheral artery disease. Radiation-induced fibrosis, vascular cell damage and oxidative stress can lead to these and other late side-effect symptoms.[75]

Pathophysiology

 
Density-Dependent Colour Scanning Electron Micrograph SEM (DDC-SEM) of cardiovascular calcification, showing in orange calcium phosphate spherical particles (denser material) and, in green, the extracellular matrix (less dense material)[77]

Population-based studies show that atherosclerosis, the major precursor of cardiovascular disease, begins in childhood. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study demonstrated that intimal lesions appear in all the aortas and more than half of the right coronary arteries of youths aged 7–9 years.[78]

Obesity and diabetes mellitus are linked to cardiovascular disease,[79] as are a history of chronic kidney disease and hypercholesterolaemia.[80] In fact, cardiovascular disease is the most life-threatening of the diabetic complications and diabetics are two- to four-fold more likely to die of cardiovascular-related causes than nondiabetics.[81][82][83]

Screening

Screening ECGs (either at rest or with exercise) are not recommended in those without symptoms who are at low risk.[84] This includes those who are young without risk factors.[85] In those at higher risk the evidence for screening with ECGs is inconclusive.[86] Additionally echocardiography, myocardial perfusion imaging, and cardiac stress testing is not recommended in those at low risk who do not have symptoms.[87] Some biomarkers may add to conventional cardiovascular risk factors in predicting the risk of future cardiovascular disease; however, the value of some biomarkers is questionable.[88][89] Ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP), and coronary artery calcium, are also of unclear benefit in those without symptoms as of 2018.[90]

The NIH recommends lipid testing in children beginning at the age of 2 if there is a family history of heart disease or lipid problems.[91] It is hoped that early testing will improve lifestyle factors in those at risk such as diet and exercise.[92]

Screening and selection for primary prevention interventions has traditionally been done through absolute risk using a variety of scores (ex. Framingham or Reynolds risk scores).[93] This stratification has separated people who receive the lifestyle interventions (generally lower and intermediate risk) from the medication (higher risk). The number and variety of risk scores available for use has multiplied, but their efficacy according to a 2016 review was unclear due to lack of external validation or impact analysis.[94] Risk stratification models often lack sensitivity for population groups and do not account for the large number of negative events among the intermediate and low risk groups.[93] As a result, future preventative screening appears to shift toward applying prevention according to randomized trial results of each intervention rather than large-scale risk assessment.

Prevention

Up to 90% of cardiovascular disease may be preventable if established risk factors are avoided.[9][95] Currently practised measures to prevent cardiovascular disease include:

  • Maintaining a healthy diet, such as the Mediterranean diet, a vegetarian, vegan or another plant-based diet.[96][97][98][99]
  • Replacing saturated fat with healthier choices: Clinical trials show that replacing saturated fat with polyunsaturated vegetable oil reduced CVD by 30%. Prospective observational studies show that in many populations lower intake of saturated fat coupled with higher intake of polyunsaturated and monounsaturated fat is associated with lower rates of CVD.[100]
  • Decrease body fat if overweight or obese.[101] The effect of weight loss is often difficult to distinguish from dietary change, and evidence on weight reducing diets is limited.[102] In observational studies of people with severe obesity, weight loss following bariatric surgery is associated with a 46% reduction in cardiovascular risk.[103]
  • Limit alcohol consumption to the recommended daily limits.[96] People who moderately consume alcoholic drinks have a 25–30% lower risk of cardiovascular disease.[104][105] However, people who are genetically predisposed to consume less alcohol have lower rates of cardiovascular disease[106] suggesting that alcohol itself may not be protective. Excessive alcohol intake increases the risk of cardiovascular disease[107][105] and consumption of alcohol is associated with increased risk of a cardiovascular event in the day following consumption.[105]
  • Decrease non-HDL cholesterol.[108][109] Statin treatment reduces cardiovascular mortality by about 31%.[110]
  • Stopping smoking and avoidance of second-hand smoke.[96] Stopping smoking reduces risk by about 35%.[111]
  • At least 150 minutes (2 hours and 30 minutes) of moderate exercise per week.[112][113]
  • Lower blood pressure, if elevated. A 10 mmHg reduction in blood pressure reduces risk by about 20%.[114] Lowering blood pressure appears to be effective even at normal blood pressure ranges.[115][116][117]
  • Decrease psychosocial stress.[118] This measure may be complicated by imprecise definitions of what constitute psychosocial interventions.[119] Mental stress–induced myocardial ischemia is associated with an increased risk of heart problems in those with previous heart disease.[120] Severe emotional and physical stress leads to a form of heart dysfunction known as Takotsubo syndrome in some people.[121] Stress, however, plays a relatively minor role in hypertension.[122] Specific relaxation therapies are of unclear benefit.[123][124]
  • Not enough sleep also raises the risk of high blood pressure. Adults need about 7–9 hours of sleep. Sleep apnea is also a major risk as it causes breathing to stop briefly, which can put stress on the body which can raise the risk of heart disease.[125][126]

Most guidelines recommend combining preventive strategies. There is some evidence that interventions aiming to reduce more than one cardiovascular risk factor may have beneficial effects on blood pressure, body mass index and waist circumference; however, evidence was limited and the authors were unable to draw firm conclusions on the effects on cardiovascular events and mortality.[127]

There is additional evidence to suggest that providing people with a cardiovascular disease risk score may reduce risk factors by a small amount compared to usual care.[128] However, there was some uncertainty as to whether providing these scores had any effect on cardiovascular disease events. It is unclear whether or not dental care in those with periodontitis affects their risk of cardiovascular disease.[129]

Diet

See also: Lipid hypothesis, Saturated fat and cardiovascular disease, and Salt and cardiovascular disease

A diet high in fruits and vegetables decreases the risk of cardiovascular disease and death.[130]

A 2021 review found that plant-based diets can provide a risk reduction for CVD if a healthy plant-based diet is consumed. Unhealthy plant-based diets do not provide benefits over diets including meat.[97] A similar meta-analysis and systematic review also looked into dietary patterns and found "that diets lower in animal foods and unhealthy plant foods, and higher in healthy plant foods are beneficial for CVD prevention".[98] A 2018 meta-analysis of observational studies concluded that "In most countries, a vegan diet is associated with a more favourable cardio-metabolic profile compared to an omnivorous diet."[99]

Evidence suggests that the Mediterranean diet may improve cardiovascular outcomes.[131] There is also evidence that a Mediterranean diet may be more effective than a low-fat diet in bringing about long-term changes to cardiovascular risk factors (e.g., lower cholesterol level and blood pressure).[132]

The DASH diet (high in nuts, fish, fruits and vegetables, and low in sweets, red meat and fat) has been shown to reduce blood pressure,[133] lower total and low density lipoprotein cholesterol[134] and improve metabolic syndrome;[135] but the long-term benefits have been questioned.[136] A high-fiber diet is associated with lower risks of cardiovascular disease.[137]

Worldwide, dietary guidelines recommend a reduction in saturated fat,[138] and although the role of dietary fat in cardiovascular disease is complex and controversial there is a long-standing consensus that replacing saturated fat with unsaturated fat in the diet is sound medical advice.[139] Total fat intake has not been found to be associated with cardiovascular risk.[140][141] A 2020 systematic review found moderate quality evidence that reducing saturated fat intake for at least 2 years caused a reduction in cardiovascular events.[142] A 2015 meta-analysis of observational studies however did not find a convincing association between saturated fat intake and cardiovascular disease.[143] Variation in what is used as a substitute for saturated fat may explain some differences in findings.[139] The benefit from replacement with polyunsaturated fats appears greatest,[144] while replacement of saturated fats with carbohydrates does not appear to have a beneficial effect.[144] A diet high in trans fatty acids is associated with higher rates of cardiovascular disease,[145] and in 2015 the Food and Drug Administration (FDA) determined that there was 'no longer a consensus among qualified experts that partially hydrogenated oils (PHOs), which are the primary dietary source of industrially produced trans fatty acids (IP-TFA), are generally recognized as safe (GRAS) for any use in human food'.[146] There is conflicting evidence concerning whether dietary supplements of omega-3 fatty acids (a type of polyunsaturated fat in oily fish) added to diet improve cardiovascular risk.[147][148]

The benefits of recommending a low-salt diet in people with high or normal blood pressure are not clear.[149] In those with heart failure, after one study was left out, the rest of the trials show a trend to benefit.[150][151] Another review of dietary salt concluded that there is strong evidence that high dietary salt intake increases blood pressure and worsens hypertension, and that it increases the number of cardiovascular disease events; both as a result of the increased blood pressure and probably through other mechanisms.[152][153] Moderate evidence was found that high salt intake increases cardiovascular mortality; and some evidence was found for an increase in overall mortality, strokes, and left ventricular hypertrophy.[152]

Intermittent fasting

Overall, the current body of scientific evidence is uncertain on whether intermittent fasting could prevent cardiovascular disease.[154] Intermittent fasting may help people lose more weight than regular eating patterns, but was not different from energy restriction diets.[154]

Medication

Blood pressure medication reduces cardiovascular disease in people at risk,[114] irrespective of age,[155] the baseline level of cardiovascular risk,[156] or baseline blood pressure.[157] The commonly-used drug regimens have similar efficacy in reducing the risk of all major cardiovascular events, although there may be differences between drugs in their ability to prevent specific outcomes.[158] Larger reductions in blood pressure produce larger reductions in risk,[158] and most people with high blood pressure require more than one drug to achieve adequate reduction in blood pressure.[159] Adherence to medications is often poor, and while mobile phone text messaging has been tried to improve adherence, there is insufficient evidence that it alters secondary prevention of cardiovascular disease.[160]

Statins are effective in preventing further cardiovascular disease in people with a history of cardiovascular disease.[161] As the event rate is higher in men than in women, the decrease in events is more easily seen in men than women.[161] In those at risk, but without a history of cardiovascular disease (primary prevention), statins decrease the risk of death and combined fatal and non-fatal cardiovascular disease.[162] The benefit, however, is small.[163] A United States guideline recommends statins in those who have a 12% or greater risk of cardiovascular disease over the next ten years.[164] Niacin, fibrates and CETP Inhibitors, while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins.[165] Fibrates lower the risk of cardiovascular and coronary events, but there is no evidence to suggest that they reduce all-cause mortality.[166]

Anti-diabetic medication may reduce cardiovascular risk in people with Type 2 diabetes, although evidence is not conclusive.[167] A meta-analysis in 2009 including 27,049 participants and 2,370 major vascular events showed a 15% relative risk reduction in cardiovascular disease with more-intensive glucose lowering over an average follow-up period of 4.4 years, but an increased risk of major hypoglycemia.[168]

Aspirin has been found to be of only modest benefit in those at low risk of heart disease, as the risk of serious bleeding is almost equal to the protection against cardiovascular problems.[169] In those at very low risk, including those over the age of 70, it is not recommended.[170][171] The United States Preventive Services Task Force recommends against use of aspirin for prevention in women less than 55 and men less than 45 years old; however, it is recommended for some older people.[172]

The use of vasoactive agents for people with pulmonary hypertension with left heart disease or hypoxemic lung diseases may cause harm and unnecessary expense.[173]

Antibiotics for secondary prevention of coronary heart disease

Antibiotics may help patients with coronary disease to reduce the risk of heart attacks and strokes.[174] However, evidence in 2021 suggests that antibiotics for secondary prevention of coronary heart disease are harmful, with increased mortality and occurrence of stroke;[174] the use of antibiotics is not supported for preventing secondary coronary heart disease.

Physical activity

Exercise-based cardiac rehabilitation following a heart attack reduces the risk of death from cardiovascular disease and leads to less hospitalizations.[175] There have been few high-quality studies of the benefits of exercise training in people with increased cardiovascular risk but no history of cardiovascular disease.[176]

A systematic review estimated that inactivity is responsible for 6% of the burden of disease from coronary heart disease worldwide.[177] The authors estimated that 121,000 deaths from coronary heart disease could have been averted in Europe in 2008 if people had not been physically inactive. Low-quality evidence from a limited number of studies suggest that yoga has beneficial effects on blood pressure and cholesterol.[178] Tentative evidence suggests that home-based exercise programs may be more efficient at improving exercise adherence.[179]

Dietary supplements

While a healthy diet is beneficial, the effect of antioxidant supplementation (vitamin E, vitamin C, etc.) or vitamins has not been shown to protect against cardiovascular disease and in some cases may possibly result in harm.[180][181][182][183] Mineral supplements have also not been found to be useful.[184] Niacin, a type of vitamin B3, may be an exception with a modest decrease in the risk of cardiovascular events in those at high risk.[185][186] Magnesium supplementation lowers high blood pressure in a dose-dependent manner.[187] Magnesium therapy is recommended for people with ventricular arrhythmia associated with torsades de pointes who present with long QT syndrome, and for the treatment of people with digoxin intoxication-induced arrhythmias.[188] There is no evidence that omega-3 fatty acid supplementation is beneficial.[189] A 2022 review found that some dietary supplements, including micronutrients, may reduce risk factors for cardiovascular disease.[190]

Management

Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.[3] Influenza may make heart attacks and strokes more likely and therefore influenza vaccination may decrease the chance of cardiovascular events and death in people with heart disease.[191]

Proper CVD management necessitates a focus on MI and stroke cases due to their combined high mortality rate, keeping in mind the cost-effectiveness of any intervention, especially in developing countries with low or middle-income levels.[93] Regarding MI, strategies using aspirin, atenolol, streptokinase or tissue plasminogen activator have been compared for quality-adjusted life-year (QALY) in regions of low and middle income. The costs for a single QALY for aspirin and atenolol were less than US$25, streptokinase was about $680, and t-PA was $16,000.[192] Aspirin, ACE inhibitors, beta-blockers, and statins used together for secondary CVD prevention in the same regions showed single QALY costs of $350.[192]

There are also surgical or procedural interventions that can save someone's life or prolong it. For heart valve problems, a person could have surgery to replace the valve. For arrhythmias, a pacemaker can be put in place to help reduce abnormal heart rhythms and for a heart attack, there are multiple options two of these are a coronary angioplasty and a coronary artery bypass surgery.[193]

There is probably no additional benefit in terms of mortality and serious adverse events when blood pressure targets were lowered to ≤ 135/85 mmHg from ≤ 140 to 160/90 to 100 mmHg.[194]

Epidemiology

 
Cardiovascular diseases deaths per million persons in 2012
  318–925
  926–1,148
  1,149–1,294
  1,295–1,449
  1,450–1,802
  1,803–2,098
  2,099–2,624
  2,625–3,203
  3,204–5,271
  5,272–10233
 
Disability-adjusted life year for cardiovascular diseases per 100,000 inhabitants in 2004[16]
  no data
  <900
  900–1650
  1650–2300
  2300–3000
  3000–3700
  3700–4400
  4400–5100
  5100–5800
  5800–6500
  6500–7200
  7200–7900
  >7900

Cardiovascular diseases are the leading cause of death worldwide and in all regions except Africa.[3] In 2008, 30% of all global death was attributed to cardiovascular diseases. Death caused by cardiovascular diseases are also higher in low- and middle-income countries as over 80% of all global deaths caused by cardiovascular diseases occurred in those countries. It is also estimated that by 2030, over 23 million people will die from cardiovascular diseases each year.

It is estimated that 60% of the world's cardiovascular disease burden will occur in the South Asian subcontinent despite only accounting for 20% of the world's population. This may be secondary to a combination of genetic predisposition and environmental factors. Organizations such as the Indian Heart Association are working with the World Heart Federation to raise awareness about this issue.[195]

Research

See also: Heart-on-a-chip and Vessel-on-a-chip

There is evidence that cardiovascular disease existed in pre-history,[196] and research into cardiovascular disease dates from at least the 18th century.[197] The causes, prevention, and/or treatment of all forms of cardiovascular disease remain active fields of biomedical research, with hundreds of scientific studies being published on a weekly basis.

Recent areas of research include the link between inflammation and atherosclerosis[198] the potential for novel therapeutic interventions,[199] and the genetics of coronary heart disease.[200]

References

  1. ^ "Heart disease". Mayo Clinic. 2022-08-25.
  2. ^ a b Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. (January 2013). "Heart disease and stroke statistics--2013 update: a report from the American Heart Association". Circulation. 127 (1): e6–e245. doi:10.1161/cir.0b013e31828124ad. PMC 5408511. PMID 23239837.
  3. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad Shanthi M, Pekka P, Norrving B (2011). Global Atlas on Cardiovascular Disease Prevention and Control (PDF). World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. pp. 3–18. ISBN 978-92-4-156437-3. (PDF) from the original on 2014-08-17.
  4. ^ a b c Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. (GBD 2013 Mortality and Causes of Death Collaborators) (January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
  5. ^ a b Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. (GBD 2015 Mortality and Causes of Death Collaborators) (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  6. ^ Petersen, Kristina S.; Kris-Etherton, Penny M. (2021-11-28). "Diet quality assessment and the relationship between diet quality and cardiovascular disease risk". Nutrients. 13 (12): 4305. doi:10.3390/nu13124305. ISSN 2072-6643. PMC 8706326. PMID 34959857.
  7. ^ a b Jackson CL, Redline S, Emmons KM (March 2015). "Sleep as a potential fundamental contributor to disparities in cardiovascular health". Annual Review of Public Health. 36 (1): 417–40. doi:10.1146/annurev-publhealth-031914-122838. PMC 4736723. PMID 25785893.
  8. ^ a b Wang R, Dong Y, Weng J, Kontos EZ, Chervin RD, Rosen CL, et al. (January 2017). "Associations among Neighborhood, Race, and Sleep Apnea Severity in Children. A Six-City Analysis". Annals of the American Thoracic Society. 14 (1): 76–84. doi:10.1513/AnnalsATS.201609-662OC. PMC 5291481. PMID 27768852.
  9. ^ a b McGill HC, McMahan CA, Gidding SS (March 2008). "Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study". Circulation. 117 (9): 1216–27. doi:10.1161/CIRCULATIONAHA.107.717033. PMID 18316498.
  10. ^ O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. (August 2016). "Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study". Lancet. 388 (10046): 761–75. doi:10.1016/S0140-6736(16)30506-2. PMID 27431356. S2CID 39752176.
  11. ^ Spinks, Anneliese; Glasziou, Paul P.; Del Mar, Chris B. (2021-12-09). "Antibiotics for treatment of sore throat in children and adults". The Cochrane Database of Systematic Reviews. 2021 (12): CD000023. doi:10.1002/14651858.CD000023.pub5. ISSN 1469-493X. PMC 8655103. PMID 34881426.
  12. ^ Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, et al. (2013). "Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials". PLOS ONE. 8 (12): e81970. Bibcode:2013PLoSO...881970S. doi:10.1371/journal.pone.0081970. PMC 3855368. PMID 24339983.
  13. ^ Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al. (September 2013). "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews". Health Technology Assessment. 17 (43): 1–253. doi:10.3310/hta17430. PMC 4781046. PMID 24074752.
  14. ^ a b Institute of Medicine of the National Academies (2010). "Epidemiology of Cardiovascular Disease". In Fuster V, Kelly BB (eds.). Promoting cardiovascular health in the developing world : a critical challenge to achieve global health. Washington, DC: National Academies Press. ISBN 978-0-309-14774-3. from the original on 2017-09-08.
  15. ^ Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, Naghavi M (April 2014). "Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study". Circulation. 129 (14): 1483–92. doi:10.1161/circulationaha.113.004042. PMC 4181359. PMID 24573352.
  16. ^ a b . World Health Organization. 2009. Archived from the original on 2009-11-11.
  17. ^ Fuster V, Kelly BB, eds. (2010). Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, DC: National Academies Press. ISBN 978-0-309-14774-3.
  18. ^ Finks SW, Airee A, Chow SL, Macaulay TE, Moranville MP, Rogers KC, Trujillo TC (April 2012). "Key articles of dietary interventions that influence cardiovascular mortality". Pharmacotherapy. 32 (4): e54-87. doi:10.1002/j.1875-9114.2011.01087.x. PMID 22392596. S2CID 36437057.
  19. ^ a b Micha R, Michas G, Mozaffarian D (December 2012). "Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes--an updated review of the evidence". Current Atherosclerosis Reports. 14 (6): 515–24. doi:10.1007/s11883-012-0282-8. PMC 3483430. PMID 23001745.
  20. ^ a b Ciaccio EJ, Lewis SK, Biviano AB, Iyer V, Garan H, Green PH (August 2017). "Cardiovascular involvement in celiac disease". World Journal of Cardiology (Review). 9 (8): 652–666. doi:10.4330/wjc.v9.i8.652. PMC 5583538. PMID 28932354.
  21. ^ Duell, PB; Welty, FK; Miller, M; Chait, A; Hammond, G; Ahmad, Z; Cohen, DE; Horton, JD; Pressman, GS; Toth, PP; American Heart Association Council on Atherosclerosis, Thrombosis, and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease (April 2022). "Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association". Arteriosclerosis, Thrombosis, and Vascular Biology. 42 (6): e168–e185. doi:10.1161/ATV.0000000000000153. PMID 35418240. S2CID 248155592.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study". Lancet. 364 (9438): 937–52. doi:10.1016/S0140-6736(04)17018-9. hdl:10983/21615. PMID 15364185. S2CID 30811593.
  23. ^ McPhee S (2012). Current medical diagnosis & treatment. New York: McGraw-Hill Medical. pp. 430. ISBN 978-0-07-176372-1.
  24. ^ Eckel RH (November 1997). "Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association". Circulation. 96 (9): 3248–50. doi:10.1161/01.CIR.96.9.3248. PMID 9386201.
  25. ^ Kathiresan S, Srivastava D (March 2012). "Genetics of human cardiovascular disease". Cell. 148 (6): 1242–57. doi:10.1016/j.cell.2012.03.001. PMC 3319439. PMID 22424232.
  26. ^ a b Semsarian, Christopher; Ingles, Jodie; Ross, Samantha Barratt; Dunwoodie, Sally L.; Bagnall, Richard D.; Kovacic, Jason C. (2021-05-25). "Precision Medicine in Cardiovascular Disease: Genetics and Impact on Phenotypes: JACC Focus Seminar 1/5". Journal of the American College of Cardiology. 77 (20): 2517–2530. doi:10.1016/j.jacc.2020.12.071. ISSN 0735-1097. PMID 34016265. S2CID 235073575.
  27. ^ Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. (October 2015). "A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease" (PDF). Nature Genetics. 47 (10): 1121–1130. doi:10.1038/ng.3396. PMC 4589895. PMID 26343387 – via University of Dundee.
  28. ^ MacRae CA, Vasan RS (June 2016). "The Future of Genetics and Genomics: Closing the Phenotype Gap in Precision Medicine". Circulation. 133 (25): 2634–9. doi:10.1161/CIRCULATIONAHA.116.022547. PMC 6188655. PMID 27324359.
  29. ^ a b c Finegold JA, Asaria P, Francis DP (September 2013). "Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations". International Journal of Cardiology. 168 (2): 934–45. doi:10.1016/j.ijcard.2012.10.046. PMC 3819990. PMID 23218570.
  30. ^ D'Adamo E, Guardamagna O, Chiarelli F, Bartuli A, Liccardo D, Ferrari F, Nobili V (2015). "Atherogenic dyslipidemia and cardiovascular risk factors in obese children". International Journal of Endocrinology. 2015: 912047. doi:10.1155/2015/912047. PMC 4309297. PMID 25663838.
  31. ^ "Understand Your Risk of Heart Attack". American Heart Association.http://www.heart.org/HEARTORG/Conditions/HeartAttack/UnderstandYourRiskofHeartAttack/Understand-Your-Risk-of-Heart-Attack_UCM_002040_Article.jsp
  32. ^ Mackay, Judith; Mensah, George; Mendis, Shanthi; Greenland, Kurt (January 2004). The Atlas of Heart Disease and Stroke. World Health Organization and U. S. Centers for Disease Control and Prevention. hdl:10665/43007. ISBN 978-92-4-156276-8.
  33. ^ a b c d e f g Jousilahti P, Vartiainen E, Tuomilehto J, Puska P (March 1999). "Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland". Circulation. 99 (9): 1165–72. doi:10.1161/01.cir.99.9.1165. PMID 10069784.
  34. ^ a b c d Jani B, Rajkumar C (June 2006). "Ageing and vascular ageing". Postgraduate Medical Journal. 82 (968): 357–62. doi:10.1136/pgmj.2005.036053. PMC 2563742. PMID 16754702.
  35. ^ a b . World Heart Federation. 2012. Archived from the original on 2012-05-10.
  36. ^ "Diabetes raises women's risk of heart disease more than for men". NPR.org. May 22, 2014. from the original on May 23, 2014. Retrieved May 23, 2014.
  37. ^ "Pregnancy complications increase the risk of heart attacks and stroke in women with high blood pressure". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2023-11-21. doi:10.3310/nihrevidence_60660.
  38. ^ Al Khalaf S, Chappell LC, Khashan AS, McCarthy FP, O'Reilly ÉJ (July 2023). "Association Between Chronic Hypertension and the Risk of 12 Cardiovascular Diseases Among Parous Women: The Role of Adverse Pregnancy Outcomes". Hypertension. 80 (7): 1427–1438. doi:10.1161/HYPERTENSIONAHA.122.20628. PMID 37170819.
  39. ^ Jackson R, Chambles L, Higgins M, Kuulasmaa K, Wijnberg L, Williams D (WHO MONICA Project, and ARIC Study.) Sex difference in ischaemic heart disease mortality and risk factors in 46 communities: an ecologic analysis. Cardiovasc Risk Factors. 1999; 7:43–54.
  40. ^ Doll R, Peto R, Boreham J, Sutherland I (June 2004). "Mortality in relation to smoking: 50 years' observations on male British doctors". BMJ. 328 (7455): 1519. doi:10.1136/bmj.38142.554479.AE. PMC 437139. PMID 15213107.
  41. ^ World Health Organization; UNAIDS (2007). Prevention of Cardiovascular Disease. World Health Organization. pp. 3–. ISBN 978-92-4-154726-0. from the original on 27 April 2016.
  42. ^ Hooper L, Martin N, Jimoh OF, Kirk C, Foster E, Abdelhamid AS (August 2020). "Reduction in saturated fat intake for cardiovascular disease". The Cochrane Database of Systematic Reviews. 2020 (8): CD011737. doi:10.1002/14651858.CD011737.pub3. PMC 8092457. PMID 32827219.
  43. ^ Booker CS, Mann JI (July 2008). "Trans fatty acids and cardiovascular health: translation of the evidence base". Nutrition, Metabolism, and Cardiovascular Diseases. 18 (6): 448–56. doi:10.1016/j.numecd.2008.02.005. PMID 18468872.
  44. ^ Remig V, Franklin B, Margolis S, Kostas G, Nece T, Street JC (April 2010). "Trans fats in America: a review of their use, consumption, health implications, and regulation". Journal of the American Dietetic Association. 110 (4): 585–92. doi:10.1016/j.jada.2009.12.024. hdl:2097/6377. PMID 20338284.
  45. ^ a b "WHO plan to eliminate industrially-produced trans-fatty acids from global food supply" (Press release). World Health Organization. 14 May 2018.
  46. ^ Te Morenga LA, Howatson AJ, Jones RM, Mann J (July 2014). "Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids". The American Journal of Clinical Nutrition. 100 (1): 65–79. doi:10.3945/ajcn.113.081521. PMID 24808490.
  47. ^ Howard, BV; Wylie-Rosett, J (Jul 23, 2002). "Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association". Circulation. 106 (4): 523–7. doi:10.1161/01.cir.0000019552.77778.04. PMID 12135957. S2CID 1589727.
  48. ^ Bell S, Daskalopoulou M, Rapsomaniki E, George J, Britton A, Bobak M, et al. (March 2017). "Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases: population based cohort study using linked health records". BMJ. 356: j909. doi:10.1136/bmj.j909. PMC 5594422. PMID 28331015.
  49. ^ Mukamal KJ, Chen CM, Rao SR, Breslow RA (March 2010). "Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002". Journal of the American College of Cardiology. 55 (13): 1328–35. doi:10.1016/j.jacc.2009.10.056. PMC 3865979. PMID 20338493.
  50. ^ Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. (May 2019). "Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China". Lancet. 393 (10183): 1831–1842. doi:10.1016/S0140-6736(18)31772-0. PMC 6497989. PMID 30955975.
  51. ^ World Health Organization (2011). Global Status Report on Alcohol and Health. World Health Organization. ISBN 978-92-4-156415-1. from the original on 2016-05-07.
  52. ^ Cespedes Feliciano EM, Quante M, Rifas-Shiman SL, Redline S, Oken E, Taveras EM (July 2018). "Objective Sleep Characteristics and Cardiometabolic Health in Young Adolescents". Pediatrics. 142 (1): e20174085. doi:10.1542/peds.2017-4085. PMC 6260972. PMID 29907703. Retrieved 28 June 2021.
  53. ^ St-Onge MP, Grandner MA, Brown D, Conroy MB, Jean-Louis G, Coons M, Bhatt DL (November 2016). "Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association". Circulation (Review). 134 (18): e367–e386. doi:10.1161/CIR.0000000000000444. PMC 5567876. PMID 27647451.
  54. ^ a b c Di Cesare M, Khang YH, Asaria P, Blakely T, Cowan MJ, Farzadfar F, et al. (February 2013). "Inequalities in non-communicable diseases and effective responses". Lancet. 381 (9866): 585–97. doi:10.1016/S0140-6736(12)61851-0. hdl:10906/80012. PMID 23410608. S2CID 41892834.
  55. ^ Mackenbach JP, Cavelaars AE, Kunst AE, Groenhof F (July 2000). "Socioeconomic inequalities in cardiovascular disease mortality; an international study". European Heart Journal. 21 (14): 1141–51. doi:10.1053/euhj.1999.1990. PMID 10924297. S2CID 8747779.
  56. ^ Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A (November 2009). "Socioeconomic status and cardiovascular disease: risks and implications for care". Nature Reviews. Cardiology. 6 (11): 712–22. doi:10.1038/nrcardio.2009.163. PMID 19770848. S2CID 21835944.
  57. ^ World Health Organization (2008). Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health : Commission on Social Determinants of Health Final Report. World Health Organization. pp. 26–. ISBN 978-92-4-156370-3. from the original on 2016-05-01.
  58. ^ a b c d Franchini M, Mannucci PM (March 2012). "Air pollution and cardiovascular disease". Thrombosis Research. 129 (3): 230–4. doi:10.1016/j.thromres.2011.10.030. PMID 22113148.
  59. ^ a b Sun Q, Hong X, Wold LE (June 2010). "Cardiovascular effects of ambient particulate air pollution exposure". Circulation. 121 (25): 2755–65. doi:10.1161/CIRCULATIONAHA.109.893461. PMC 2924678. PMID 20585020.
  60. ^ a b Tunstall-Pedoe H (March 2011). "Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose". Heart. 97 (6): 442–4. doi:10.1136/hrt.2010.214858. PMID 21339319. S2CID 6420111.
  61. ^ World Health Organization (2007). Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. World Health Organization. ISBN 978-92-4-154717-8. from the original on 2016-05-06.
  62. ^ van Staa TP, Gulliford M, Ng ES, Goldacre B, Smeeth L (2014). "Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?". PLOS ONE. 9 (10): e106455. Bibcode:2014PLoSO...9j6455V. doi:10.1371/journal.pone.0106455. PMC 4182667. PMID 25271417.  
  63. ^ Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al. (May 2009). "Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association". Circulation. 119 (17): 2408–16. doi:10.1161/CIRCULATIONAHA.109.192278. PMC 2956982. PMID 19364974.
  64. ^ Eckel RH, Cornier MA (August 2014). "Update on the NCEP ATP-III emerging cardiometabolic risk factors". BMC Medicine. 12 (1): 115. doi:10.1186/1741-7015-12-115. PMC 4283079. PMID 25154373.  
  65. ^ Bai W, Li J, Liu J (October 2016). "Serum phosphorus, cardiovascular and all-cause mortality in the general population: A meta-analysis". Clinica Chimica Acta; International Journal of Clinical Chemistry. 461: 76–82. doi:10.1016/j.cca.2016.07.020. PMID 27475981.
  66. ^ Cohen BE, Edmondson D, Kronish IM (November 2015). "State of the Art Review: Depression, Stress, Anxiety, and Cardiovascular Disease". American Journal of Hypertension. 28 (11): 1295–302. doi:10.1093/ajh/hpv047. PMC 4612342. PMID 25911639.
  67. ^ Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM (November 2013). "Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review". American Heart Journal. 166 (5): 806–14. doi:10.1016/j.ahj.2013.07.031. PMC 3815706. PMID 24176435.
  68. ^ "NIOSH Program Portfolio : Cancer, Reproductive, and Cardiovascular Diseases : Program Description". CDC. from the original on 2016-05-15. Retrieved 2016-06-07.
  69. ^ a b c d e f g h Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) (2015-08-26). "Occupational Exposures and Cardiovascular Disease". www.sbu.se. from the original on 2017-06-14. Retrieved 2017-06-01.
  70. ^ a b c d e Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). . www.sbu.se. Archived from the original on 2017-06-06. Retrieved 2017-06-01.
  71. ^ Jan M, Ebert BL, Jaiswal S (January 2017). "Clonal hematopoiesis". Seminars in Hematology. 54 (1): 43–50. doi:10.1053/j.seminhematol.2016.10.002. PMC 8045769. PMID 28088988.
  72. ^ Taylor CW, Nisbet A, McGale P, Darby SC (December 2007). "Cardiac exposures in breast cancer radiotherapy: 1950s-1990s". International Journal of Radiation Oncology, Biology, Physics. 69 (5): 1484–95. doi:10.1016/j.ijrobp.2007.05.034. PMID 18035211.
  73. ^ Weintraub NL, Jones WK, Manka D (March 2010). "Understanding radiation-induced vascular disease". Journal of the American College of Cardiology. 55 (12): 1237–1239. doi:10.1016/j.jacc.2009.11.053. PMC 3807611. PMID 20298931.
  74. ^ a b Benveniste, Marcelo F.; Gomez, Daniel; Carter, Brett W.; Betancourt Cuellar, Sonia L.; Shroff, Girish S.; Benveniste, Ana Paula; Odisio, Erika G.; Marom, Edith M. (March 7, 2019). "Recognizing Radiation Therapy–related Complications in the Chest". RadioGraphics. 39 (2): 353. doi:10.1148/rg.2019180061. PMID 30844346. S2CID 73477338. Retrieved 24 August 2023.
  75. ^ a b Klee NS, McCarthy CG, Martinez-Quinones P, Webb RC (November 2017). "Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy". Therapeutic Advances in Cardiovascular Disease. 11 (11): 297–317. doi:10.1177/1753944717729141. PMC 5933669. PMID 28911261.
  76. ^ Belzile-Dugas E, Eisenberg MJ (September 2021). "Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology". J Am Heart Assoc. 10 (18): e021686. doi:10.1161/JAHA.121.021686. PMC 8649542. PMID 34482706.
  77. ^ Bertazzo S, Gentleman E, Cloyd KL, Chester AH, Yacoub MH, Stevens MM (June 2013). "Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification". Nature Materials. 12 (6): 576–83. Bibcode:2013NatMa..12..576B. doi:10.1038/nmat3627. PMC 5833942. PMID 23603848.
  78. ^ Vanhecke TE, Miller WM, Franklin BA, Weber JE, McCullough PA (October 2006). "Awareness, knowledge, and perception of heart disease among adolescents". European Journal of Cardiovascular Prevention and Rehabilitation. 13 (5): 718–23. doi:10.1097/01.hjr.0000214611.91490.5e. PMID 17001210. S2CID 36312234.
  79. ^ Highlander P, Shaw GP (February 2010). "Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics". Therapeutic Advances in Cardiovascular Disease. 4 (1): 43–54. doi:10.1177/1753944709354305. PMID 19965897. S2CID 23913203.
  80. ^ NPS Medicinewise (1 March 2011). . Archived from the original on 19 March 2011. Retrieved 1 August 2011.
  81. ^ Kvan E, Pettersen KI, Sandvik L, Reikvam A (October 2007). "High mortality in diabetic patients with acute myocardial infarction: cardiovascular co-morbidities contribute most to the high risk". International Journal of Cardiology. 121 (2): 184–8. doi:10.1016/j.ijcard.2006.11.003. PMID 17184858.
  82. ^ Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L (February 2004). "Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization". Journal of the American College of Cardiology. 43 (4): 585–91. doi:10.1016/j.jacc.2003.08.050. PMID 14975468.
  83. ^ DECODE, European Diabetes Epidemiology Group (August 1999). "Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe". Lancet. 354 (9179): 617–21. doi:10.1016/S0140-6736(98)12131-1. PMID 10466661. S2CID 54227479.
  84. ^ Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. (June 2018). "Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement". JAMA. 319 (22): 2308–2314. doi:10.1001/jama.2018.6848. PMID 29896632.
  85. ^ Maron BJ, Friedman RA, Kligfield P, Levine BD, Viskin S, Chaitman BR, et al. (October 2014). "Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology". Circulation. 130 (15): 1303–34. doi:10.1161/CIR.0000000000000025. PMID 25223981.
  86. ^ Moyer VA (October 2012). "Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 157 (7): 512–8. doi:10.7326/0003-4819-157-7-201210020-00514. PMID 22847227.
  87. ^ Chou R (March 2015). "Cardiac screening with electrocardiography, stress echocardiography, or myocardial perfusion imaging: advice for high-value care from the American College of Physicians". Annals of Internal Medicine. 162 (6): 438–47. doi:10.7326/M14-1225. PMID 25775317. S2CID 207538193.
  88. ^ Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. (December 2006). "Multiple biomarkers for the prediction of first major cardiovascular events and death". The New England Journal of Medicine. 355 (25): 2631–9. doi:10.1056/NEJMoa055373. PMID 17182988. S2CID 196411135.
  89. ^ Spence JD (November 2006). "Technology Insight: ultrasound measurement of carotid plaque--patient management, genetic research, and therapy evaluation". Nature Clinical Practice. Neurology. 2 (11): 611–9. doi:10.1038/ncpneuro0324. PMID 17057748. S2CID 26077254.
  90. ^ Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. (July 2018). "Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement". JAMA. 320 (3): 272–280. doi:10.1001/jama.2018.8359. PMID 29998297.
  91. ^ Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children Adolescents (December 2011). "Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report". Pediatrics. 128 (Supplement 5): S213-56. doi:10.1542/peds.2009-2107C. PMC 4536582. PMID 22084329.
  92. ^ Saenger AK (August 2012). "Universal lipid screening in children and adolescents: a baby step toward primordial prevention?". Clinical Chemistry. 58 (8): 1179–81. doi:10.1373/clinchem.2012.182287. PMID 22510399.
  93. ^ a b c Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E (2014). Braunwald's heart disease : a textbook of cardiovascular medicine (Tenth ed.). Philadelphia. ISBN 978-1-4557-5133-4. OCLC 890409638.{{cite book}}: CS1 maint: location missing publisher (link)
  94. ^ Damen JA, Hooft L, Schuit E, Debray TP, Collins GS, Tzoulaki I, et al. (May 2016). "Prediction models for cardiovascular disease risk in the general population: systematic review". BMJ. 353: i2416. doi:10.1136/bmj.i2416. PMC 4868251. PMID 27184143.
  95. ^ McNeal CJ, Dajani T, Wilson D, Cassidy-Bushrow AE, Dickerson JB, Ory M (January 2010). "Hypercholesterolemia in youth: opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease". Current Atherosclerosis Reports. 12 (1): 20–8. doi:10.1007/s11883-009-0072-0. PMID 20425267. S2CID 37833889.
  96. ^ a b c "Heart Attack—Prevention". NHS Direct. 28 November 2019.
  97. ^ a b Quek, Jingxuan; Lim, Grace; Lim, Wen Hui; Ng, Cheng Han; So, Wei Zheng; Toh, Jonathan; Pan, Xin Hui; Chin, Yip Han; Muthiah, Mark D.; Chan, Siew Pang; Foo, Roger S. Y. (2021-11-05). "The Association of Plant-Based Diet With Cardiovascular Disease and Mortality: A Meta-Analysis and Systematic Review of Prospect Cohort Studies". Frontiers in Cardiovascular Medicine. 8: 756810. doi:10.3389/fcvm.2021.756810. ISSN 2297-055X. PMC 8604150. PMID 34805312.
  98. ^ a b Gan, Zuo Hua; Cheong, Huey Chiat; Tu, Yu-Kang; Kuo, Po-Hsiu (2021-11-05). "Association between Plant-Based Dietary Patterns and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Prospective Cohort Studies". Nutrients. 13 (11): 3952. doi:10.3390/nu13113952. ISSN 2072-6643. PMC 8624676. PMID 34836208.
  99. ^ a b Benatar, Jocelyne R.; Stewart, Ralph A. H. (2018). "Cardiometabolic risk factors in vegans; A meta-analysis of observational studies". PLOS ONE. 13 (12): e0209086. Bibcode:2018PLoSO..1309086B. doi:10.1371/journal.pone.0209086. ISSN 1932-6203. PMC 6301673. PMID 30571724.
  100. ^ Frank M. Sacks, Alice H. Lichtenstein, Jason H.Y. Wu, Lawrence J. Appel, Mark A. Creager, Penny M. Kris-Etherton, Michael Miller, Eric B. Rimm, Lawrence L. Rudel, Jennifer G. Robinson, Neil J. Stone, and Linda V. Van Horn: Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association, 15 Jun 2017, https://doi.org/10.1161/CIR.0000000000000510Circulation 2017;136:e1–e23, https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000510
  101. ^ McTigue KM, Hess R, Ziouras J (September 2006). "Obesity in older adults: a systematic review of the evidence for diagnosis and treatment". Obesity. 14 (9): 1485–97. doi:10.1038/oby.2006.171. PMID 17030958. S2CID 45241607.
  102. ^ Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A (February 2021). "Long-term effects of weight-reducing diets in people with hypertension". The Cochrane Database of Systematic Reviews. 2021 (2): CD008274. doi:10.1002/14651858.CD008274.pub4. PMC 8093137. PMID 33555049.
  103. ^ Kwok CS, Pradhan A, Khan MA, Anderson SG, Keavney BD, Myint PK, et al. (April 2014). "Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis". International Journal of Cardiology. 173 (1): 20–8. doi:10.1016/j.ijcard.2014.02.026. hdl:2164/3181. PMID 24636546.
  104. ^ Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA (February 2011). "Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis". BMJ. 342: d671. doi:10.1136/bmj.d671. PMC 3043109. PMID 21343207.
  105. ^ a b c Mostofsky E, Chahal HS, Mukamal KJ, Rimm EB, Mittleman MA (March 2016). "Alcohol and Immediate Risk of Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis". Circulation. 133 (10): 979–87. doi:10.1161/CIRCULATIONAHA.115.019743. PMC 4783255. PMID 26936862.
  106. ^ Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, et al. (July 2014). "Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data". BMJ. 349: g4164. doi:10.1136/bmj.g4164. PMC 4091648. PMID 25011450.
  107. ^ Klatsky AL (May 2009). "Alcohol and cardiovascular diseases". Expert Review of Cardiovascular Therapy. 7 (5): 499–506. doi:10.1586/erc.09.22. PMID 19419257. S2CID 23782870.
  108. ^ McMahan CA, Gidding SS, Malcom GT, Tracy RE, Strong JP, McGill HC (October 2006). "Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis". Pediatrics. 118 (4): 1447–55. doi:10.1542/peds.2006-0970. PMID 17015535. S2CID 37741456.
  109. ^ Raitakari OT, Rönnemaa T, Järvisalo MJ, Kaitosaari T, Volanen I, Kallio K, et al. (December 2005). "Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP)". Circulation. 112 (24): 3786–94. doi:10.1161/CIRCULATIONAHA.105.583195. PMID 16330680.
  110. ^ Chou R, Dana T, Blazina I, Daeges M, Jeanne TL (November 2016). "Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force". JAMA. 316 (19): 2008–2024. doi:10.1001/jama.2015.15629. PMID 27838722.
  111. ^ Critchley J, Capewell S (2004-01-01). Critchley JA (ed.). "Smoking cessation for the secondary prevention of coronary heart disease". The Cochrane Database of Systematic Reviews (1): CD003041. doi:10.1002/14651858.CD003041.pub2. PMID 14974003. (Retracted, see doi:10.1002/14651858.cd003041.pub3)
  112. ^ "Chapter 4: Active Adults". health.gov. from the original on 2017-03-13.
  113. ^ "Physical activity guidelines for adults". NHS Choices. 2018-04-26. from the original on 2017-02-19.
  114. ^ a b Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. (March 2016). "Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis". Lancet. 387 (10022): 957–967. doi:10.1016/S0140-6736(15)01225-8. PMID 26724178.
  115. ^ "Many more people could benefit from blood pressure-lowering medication". medicalxpress.com. Retrieved 14 June 2021.
  116. ^ "expert reaction to study looking at pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure | Science Media Centre". Retrieved 14 June 2021.
  117. ^ Adler A, Agodoa L, Algra A, Asselbergs FW, Beckett NS, Berge E, et al. (May 2021). "Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis". Lancet. 397 (10285): 1625–1636. doi:10.1016/S0140-6736(21)00590-0. PMC 8102467. PMID 33933205.   Available under CC BY 4.0.
  118. ^ Linden W, Stossel C, Maurice J (April 1996). "Psychosocial interventions for patients with coronary artery disease: a meta-analysis". Archives of Internal Medicine. 156 (7): 745–52. doi:10.1001/archinte.1996.00440070065008. PMID 8615707. S2CID 45312858.
  119. ^ Thompson DR, Ski CF (December 2013). "Psychosocial interventions in cardiovascular disease--what are they?" (PDF). European Journal of Preventive Cardiology. 20 (6): 916–7. doi:10.1177/2047487313494031. PMID 24169589. S2CID 35497445.
  120. ^ Wei J, Rooks C, Ramadan R, Shah AJ, Bremner JD, Quyyumi AA, et al. (July 2014). "Meta-analysis of mental stress-induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease". The American Journal of Cardiology. 114 (2): 187–92. doi:10.1016/j.amjcard.2014.04.022. PMC 4126399. PMID 24856319.
  121. ^ Pelliccia F, Greco C, Vitale C, Rosano G, Gaudio C, Kaski JC (August 2014). "Takotsubo syndrome (stress cardiomyopathy): an intriguing clinical condition in search of its identity". The American Journal of Medicine. 127 (8): 699–704. doi:10.1016/j.amjmed.2014.04.004. hdl:11573/562721. PMID 24754972.
  122. ^ Marshall IJ, Wolfe CD, McKevitt C (July 2012). "Lay perspectives on hypertension and drug adherence: systematic review of qualitative research". BMJ. 345: e3953. doi:10.1136/bmj.e3953. PMC 3392078. PMID 22777025.
  123. ^ Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. (February 2006). "Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials". Journal of Hypertension. 24 (2): 215–33. doi:10.1097/01.hjh.0000199800.72563.26. PMID 16508562. S2CID 9125890.
  124. ^ Abbott RA, Whear R, Rodgers LR, Bethel A, Thompson Coon J, Kuyken W, et al. (May 2014). "Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: A systematic review and meta-analysis of randomised controlled trials". Journal of Psychosomatic Research. 76 (5): 341–51. doi:10.1016/j.jpsychores.2014.02.012. PMID 24745774.
  125. ^ U.S. National Library of Medicine. (2021, March 24). Heart Disease Prevention. MedlinePlus. https://medlineplus.gov/howtopreventheartdisease.html.
  126. ^ U.S. Department of Health and Human Services. (n.d.). Cardiovascular Disease. National Center for Complementary and Integrative Health. https://www.nccih.nih.gov/health/cardiovascular-disease.
  127. ^ Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A (August 2015). "Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries" (PDF). The Cochrane Database of Systematic Reviews. 2015 (8): CD011163. doi:10.1002/14651858.CD011163.pub2. PMC 6999125. PMID 26272648.
  128. ^ Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD (March 2017). "Risk scoring for the primary prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 3 (6): CD006887. doi:10.1002/14651858.CD006887.pub4. PMC 6464686. PMID 28290160.
  129. ^ Ye, Zelin; Cao, Yubin; Miao, Cheng; Liu, Wei; Dong, Li; Lv, Zongkai; Iheozor-Ejiofor, Zipporah; Li, Chunjie (2022-10-04). "Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis". The Cochrane Database of Systematic Reviews. 2022 (10): CD009197. doi:10.1002/14651858.CD009197.pub5. ISSN 1469-493X. PMC 9531722. PMID 36194420.
  130. ^ Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB (July 2014). "Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies". BMJ. 349: g4490. doi:10.1136/bmj.g4490. PMC 4115152. PMID 25073782.
  131. ^ Walker C, Reamy BV (April 2009). "Diets for cardiovascular disease prevention: what is the evidence?". American Family Physician. 79 (7): 571–8. PMID 19378874.
  132. ^ Nordmann AJ, Suter-Zimmermann K, Bucher HC, Shai I, Tuttle KR, Estruch R, Briel M (September 2011). "Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors". The American Journal of Medicine. 124 (9): 841–51.e2. doi:10.1016/j.amjmed.2011.04.024. PMID 21854893. from the original on 2013-12-20.
  133. ^ Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. (January 2001). "Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group". The New England Journal of Medicine. 344 (1): 3–10. doi:10.1056/NEJM200101043440101. PMID 11136953.
  134. ^ Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER, Lin PH, et al. (July 2001). "Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial". The American Journal of Clinical Nutrition. 74 (1): 80–9. doi:10.1093/ajcn/74.1.80. PMID 11451721.
  135. ^ Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F (December 2005). "Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome". Diabetes Care. 28 (12): 2823–31. doi:10.2337/diacare.28.12.2823. PMID 16306540.
  136. ^ Logan AG (March 2007). "DASH Diet: time for a critical appraisal?". American Journal of Hypertension. 20 (3): 223–4. doi:10.1016/j.amjhyper.2006.10.006. PMID 17324730.
  137. ^ Hajishafiee M, Saneei P, Benisi-Kohansal S, Esmaillzadeh A (July 2016). "Cereal Fibre Intake and Risk of Mortality From All Causes, CVD, Cancer and Inflammatory Diseases: A Systematic Review and Meta-Analysis of Prospective Cohort Studies". The British Journal of Nutrition. 116 (2): 343–52. doi:10.1017/S0007114516001938. PMID 27193606.
  138. ^ Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. (February 2013). "Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis". BMJ. 346: e8707. doi:10.1136/bmj.e8707. PMC 4688426. PMID 23386268.
  139. ^ a b Lichtenstein AH (November 2019). "Dietary Fat and Cardiovascular Disease: Ebb and Flow Over the Last Half Century". Advances in Nutrition. 10 (Suppl_4): S332–S339. doi:10.1093/advances/nmz024. PMC 6855944. PMID 31728492.
  140. ^ Food and Agriculture Organization of the United Nations (2010). . Rome: Food and Agriculture Organization of the United Nations. ISBN 978-92-5-106733-8. OCLC 712123395. Archived from the original on 2014-12-28.
  141. ^ Willett WC (July 2012). "Dietary fats and coronary heart disease". Journal of Internal Medicine. 272 (1): 13–24. doi:10.1111/j.1365-2796.2012.02553.x. PMID 22583051. S2CID 43493760.
  142. ^ Hooper, Lee; Martin, Nicole; Jimoh, Oluseyi F.; Kirk, Christian; Foster, Eve; Abdelhamid, Asmaa S. (21 August 2020). "Reduction in saturated fat intake for cardiovascular disease". The Cochrane Database of Systematic Reviews. 2020 (8): CD011737. doi:10.1002/14651858.CD011737.pub3. ISSN 1469-493X. PMC 8092457. PMID 32827219.
  143. ^ de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. (August 2015). "Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies". BMJ. 351 (h3978): h3978. doi:10.1136/bmj.h3978. PMC 4532752. PMID 26268692.
  144. ^ a b Sacks FM, Lichtenstein AH, Wu JH, Appel LJ, Creager MA, Kris-Etherton PM, et al. (July 2017). "Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association". Circulation. 136 (3): e1–e23. doi:10.1161/CIR.0000000000000510. PMID 28620111. S2CID 367602.
  145. ^ Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. (March 2014). "Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis". Annals of Internal Medicine. 160 (6): 398–406. doi:10.7326/M13-1788. PMID 24723079. S2CID 52013596.
  146. ^ Food Drug Administration, HHS (May 2018). "Final Determination Regarding Partially Hydrogenated Oils. Notification; declaratory order; extension of compliance date". Federal Register. 83 (98): 23358–9. PMID 30019869.
  147. ^ Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. (February 2020). "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 2020 (3): CD003177. doi:10.1002/14651858.CD003177.pub5. PMC 7049091. PMID 32114706.
  148. ^ Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. (March 2018). "Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals". JAMA Cardiology. 3 (3): 225–234. doi:10.1001/jamacardio.2017.5205. PMC 5885893. PMID 29387889.
  149. ^ Adler AJ, Taylor F, Martin N, Gottlieb S, Taylor RS, Ebrahim S (December 2014). "Reduced dietary salt for the prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 2014 (12): CD009217. doi:10.1002/14651858.CD009217.pub3. PMC 6483405. PMID 25519688.
  150. ^ He FJ, MacGregor GA (July 2011). (PDF). Lancet. 378 (9789): 380–2. doi:10.1016/S0140-6736(11)61174-4. PMID 21803192. S2CID 43795786. Archived from the original (PDF) on 2013-12-20. Retrieved 2013-08-23.
  151. ^ Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P (February 2008). "Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?" (PDF). Clinical Science. 114 (3): 221–30. doi:10.1042/CS20070193. PMID 17688420. S2CID 2248777.
  152. ^ a b Bochud M, Marques-Vidal P, Burnier M, Paccaud F (2012). "Dietary Salt Intake and Cardiovascular Disease: Summarizing the Evidence". Public Health Reviews. 33 (2): 530–52. doi:10.1007/BF03391649. from the original on 2013-12-21.
  153. ^ Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. (April 2007). "Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)". BMJ. 334 (7599): 885–8. doi:10.1136/bmj.39147.604896.55. PMC 1857760. PMID 17449506.
  154. ^ a b Allaf M, Elghazaly H, Mohamed OG, Fareen MF, Zaman S, Salmasi AM, et al. (Cochrane Heart Group) (January 2021). "Intermittent fasting for the prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 1 (3): CD013496. doi:10.1002/14651858.CD013496.pub2. PMC 8092432. PMID 33512717.
  155. ^ Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. (May 2008). "Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials". BMJ. 336 (7653): 1121–3. doi:10.1136/bmj.39548.738368.BE. PMC 2386598. PMID 18480116.
  156. ^ Blood Pressure Lowering Treatment Trialists' Collaboration (August 2014). "Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data". Lancet. 384 (9943): 591–598. doi:10.1016/S0140-6736(14)61212-5. PMID 25131978. S2CID 19951800.
  157. ^ Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al. (January 2011). "The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials". Journal of Hypertension. 29 (1): 4–16. doi:10.1097/HJH.0b013e32834000be. PMID 20881867. S2CID 10374187.
  158. ^ a b Turnbull F (November 2003). "Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials". Lancet (Submitted manuscript). 362 (9395): 1527–35. doi:10.1016/s0140-6736(03)14739-3. PMID 14615107. S2CID 10730075.
  159. ^ Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E (April 2014). "An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention". Hypertension. 63 (4): 878–85. doi:10.1161/HYP.0000000000000003. PMC 10280688. PMID 24243703.
  160. ^ Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, et al. (Cochrane Heart Group) (April 2017). "Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 2017 (4): CD011851. doi:10.1002/14651858.CD011851.pub2. PMC 6478182. PMID 28455948.
  161. ^ a b Gutierrez J, Ramirez G, Rundek T, Sacco RL (June 2012). "Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis". Archives of Internal Medicine. 172 (12): 909–19. doi:10.1001/archinternmed.2012.2145. PMID 22732744.
  162. ^ Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. (January 2013). "Statins for the primary prevention of cardiovascular disease" (PDF). The Cochrane Database of Systematic Reviews. 1 (1): CD004816. doi:10.1002/14651858.CD004816.pub5. PMC 6481400. PMID 23440795.
  163. ^ "Statins in primary cardiovascular prevention?". Prescrire International. 27 (195): 183. July–August 2018. Retrieved 4 August 2018.
  164. ^ Downs JR, O'Malley PG (August 2015). "Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline". Annals of Internal Medicine. 163 (4): 291–7. doi:10.7326/m15-0840. PMID 26099117.
  165. ^ Keene D, Price C, Shun-Shin MJ, Francis DP (July 2014). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.
  166. ^ Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M, et al. (Cochrane Heart Group) (November 2016). "Fibrates for primary prevention of cardiovascular disease events". The Cochrane Database of Systematic Reviews. 11 (3): CD009753. doi:10.1002/14651858.CD009753.pub2. PMC 6464497. PMID 27849333.
  167. ^ Holman RR, Sourij H, Califf RM (June 2014). "Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes". Lancet. 383 (9933): 2008–17. doi:10.1016/s0140-6736(14)60794-7. PMID 24910232. S2CID 5064731.
  168. ^ Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. (November 2009). "Intensive glucose control and macrovascular outcomes in type 2 diabetes". Diabetologia. 52 (11): 2288–98. doi:10.1007/s00125-009-1470-0. PMID 19655124.
  169. ^ Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR (July 2011). "Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials". American Heart Journal. 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097.
  170. ^ "Final Recommendation Statement Aspirin for the Prevention of Cardiovascular Disease: Preventive Medication". March 2009. from the original on 10 January 2015. Retrieved 15 January 2015.
  171. ^ Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. (March 2019). "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Journal of the American College of Cardiology. 74 (10): e177–e232. doi:10.1016/j.jacc.2019.03.010. PMC 7685565. PMID 30894318.
  172. ^ US Preventive Services Task Force (March 2009). "Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 150 (6): 396–404. doi:10.7326/0003-4819-150-6-200903170-00008. PMID 19293072.
  173. ^ American College of Chest Physicians; American Thoracic Society (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American College of Chest Physicians and American Thoracic Society, from the original on 3 November 2013, retrieved 6 January 2013
  174. ^ a b Sethi NJ, Safi S, Korang SK, Hróbjartsson A, Skoog M, Gluud C, Jakobsen JC, et al. (Cochrane Heart Group) (February 2021). "Antibiotics for secondary prevention of coronary heart disease". The Cochrane Database of Systematic Reviews. 2 (5): CD003610. doi:10.1002/14651858.CD003610.pub4. PMC 8094925. PMID 33704780.
  175. ^ Dibben, Grace; Faulkner, James; Oldridge, Neil; Rees, Karen; Thompson, David R.; Zwisler, Ann-Dorthe; Taylor, Rod S. (6 November 2021). "Exercise-based cardiac rehabilitation for coronary heart disease". The Cochrane Database of Systematic Reviews. 2021 (11): CD001800. doi:10.1002/14651858.CD001800.pub4. ISSN 1469-493X. PMC 8571912. PMID 34741536.
  176. ^ Seron P, Lanas F, Pardo Hernandez H, Bonfill Cosp X (August 2014). "Exercise for people with high cardiovascular risk". The Cochrane Database of Systematic Reviews. 2014 (8): CD009387. doi:10.1002/14651858.CD009387.pub2. PMC 6669260. PMID 25120097.
  177. ^ Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT (July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". Lancet. 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMC 3645500. PMID 22818936.
  178. ^ Hartley L, Dyakova M, Holmes J, Clarke A, Lee MS, Ernst E, Rees K (May 2014). "Yoga for the primary prevention of cardiovascular disease" (PDF). The Cochrane Database of Systematic Reviews. 2014 (5): CD010072. doi:10.1002/14651858.CD010072.pub2. PMC 10075056. PMID 24825181.
  179. ^ Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC (January 2005). "Home versus center based physical activity programs in older adults". The Cochrane Database of Systematic Reviews. 2005 (1): CD004017. doi:10.1002/14651858.cd004017.pub2. PMC 6464851. PMID 15674925.
  180. ^ Al-Khudairy L, Flowers N, Wheelhouse R, Ghannam O, Hartley L, Stranges S, Rees K (March 2017). "Vitamin C supplementation for the primary prevention of cardiovascular disease". The Cochrane Database of Systematic Reviews. 2017 (3): CD011114. doi:10.1002/14651858.CD011114.pub2. PMC 6464316. PMID 28301692.
  181. ^ Bhupathiraju SN, Tucker KL (August 2011). "Coronary heart disease prevention: nutrients, foods, and dietary patterns". Clinica Chimica Acta; International Journal of Clinical Chemistry. 412 (17–18): 1493–514. doi:10.1016/j.cca.2011.04.038. PMC 5945285. PMID 21575619.
  182. ^ Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK, Park BJ (January 2013). "Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials". BMJ. 346: f10. doi:10.1136/bmj.f10. PMC 3548618. PMID 23335472.
  183. ^ Kim J, Choi J, Kwon SY, McEvoy JW, Blaha MJ, Blumenthal RS, et al. (July 2018). "Association of Multivitamin and Mineral Supplementation and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis". Circulation: Cardiovascular Quality and Outcomes. 11 (7): e004224. doi:10.1161/CIRCOUTCOMES.117.004224. PMID 29991644. S2CID 51615818.
  184. ^ Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP (December 2013). "Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: An updated systematic evidence review for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 159 (12): 824–34. doi:10.7326/0003-4819-159-12-201312170-00729. PMID 24217421.
  185. ^ Bruckert E, Labreuche J, Amarenco P (June 2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis". Atherosclerosis. 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.
  186. ^ Lavigne PM, Karas RH (January 2013). "The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression". Journal of the American College of Cardiology. 61 (4): 440–446. doi:10.1016/j.jacc.2012.10.030. PMID 23265337.
  187. ^ Jee SH, Miller ER, Guallar E, Singh VK, Appel LJ, Klag MJ (August 2002). "The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials". American Journal of Hypertension. 15 (8): 691–6. doi:10.1016/S0895-7061(02)02964-3. PMID 12160191.
  188. ^ Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. (September 2006). "ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation. 114 (10): e385-484. doi:10.1161/CIRCULATIONAHA.106.178233. PMID 16935995.
  189. ^ Kwak SM, Myung SK, Lee YJ, Seo HG (May 2012). "Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials". Archives of Internal Medicine. 172 (9): 686–94. doi:10.1001/archinternmed.2012.262. PMID 22493407.
  190. ^ An, Peng; Wan, Sitong; Luo, Yongting; et al. (13 December 2022). "Micronutrient supplementation to reduce cardiovascular risk". Journal of the American College of Cardiology. 80 (24): 2269–2285. doi:10.1016/j.jacc.2022.09.048. ISSN 0735-1097. PMID 36480969. S2CID 254343574.
  191. ^ Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K (May 2015). "Influenza vaccines for preventing cardiovascular disease". The Cochrane Database of Systematic Reviews. 2015 (5): CD005050. doi:10.1002/14651858.CD005050.pub3. PMC 8511741. PMID 25940444. S2CID 205176857.
  192. ^ a b Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF (2018). Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences. p. 15. ISBN 9780323555937.
  193. ^ "What is Cardiovascular Disease?". www.heart.org. 31 May 2017.
  194. ^ Saiz, Luis Carlos; Gorricho, Javier; Garjón, Javier; Celaya, Mª Concepción; Erviti, Juan; Leache, Leire (2022-11-18). "Blood pressure targets for the treatment of people with hypertension and cardiovascular disease". The Cochrane Database of Systematic Reviews. 2022 (11): CD010315. doi:10.1002/14651858.CD010315.pub5. ISSN 1469-493X. PMC 9673465. PMID 36398903.
  195. ^ Roo S. "Cardiac Disease Among South Asians: A Silent Epidemic". Indian Heart Association. from the original on 2015-05-18. Retrieved 2018-12-31.
  196. ^ Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, et al. (April 2013). "Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations". Lancet. 381 (9873): 1211–22. doi:10.1016/s0140-6736(13)60598-x. PMID 23489753. S2CID 16928278.
  197. ^ Alberti FB (2013-05-01). "John Hunter's Heart". The Bulletin of the Royal College of Surgeons of England. 95 (5): 168–69. doi:10.1308/003588413X13643054409261. ISSN 1473-6357.
  198. ^ Ruparelia N, Chai JT, Fisher EA, Choudhury RP (March 2017). "Inflammatory processes in cardiovascular disease: a route to targeted therapies". Nature Reviews. Cardiology. 14 (3): 133–144. doi:10.1038/nrcardio.2016.185. PMC 5525550. PMID 27905474.
  199. ^ Tang WH, Hazen SL (January 2017). "Atherosclerosis in 2016: Advances in new therapeutic targets for atherosclerosis". Nature Reviews. Cardiology. 14 (2): 71–72. doi:10.1038/nrcardio.2016.216. PMC 5880294. PMID 28094270.
  200. ^ Swerdlow DI, Humphries SE (February 2017). "Genetics of CHD in 2016: Common and rare genetic variants and risk of CHD". Nature Reviews. Cardiology. 14 (2): 73–74. doi:10.1038/nrcardio.2016.209. PMID 28054577. S2CID 13738641.

External links

  • WHO fact sheet on cardiovascular diseases
  • 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
  • Heart Disease MedicineNet Slides, photos, descriptions
  • Risk calculator

November 27, 2023
cardiovascular, disease, heart, condition, redirects, here, other, uses, heart, condition, disambiguation, disease, involving, heart, blood, vessels, cvds, constitute, class, diseases, that, includes, coronary, artery, diseases, angina, heart, attack, heart, f. Heart condition redirects here For other uses see Heart condition disambiguation Cardiovascular disease CVD is any disease involving the heart or blood vessels 3 CVDs constitute a class of diseases that includes coronary artery diseases e g angina heart attack heart failure hypertensive heart disease rheumatic heart disease cardiomyopathy arrhythmia congenital heart disease valvular heart disease carditis aortic aneurysms peripheral artery disease thromboembolic disease and venous thrombosis 3 4 Cardiovascular diseaseMicrograph of a heart with fibrosis yellow and amyloidosis brown Movat s stain SpecialtyCardiologySymptomsChest pain shortness of breath fatigue loss of consciousnessComplicationsHeart failure heart attack stroke aneurysm peripheral artery disease sudden cardiac arrest 1 Usual onsetOlder adults 2 TypesCoronary artery diseases stroke heart failure hypertensive heart disease rheumatic heart disease cardiomyopathy 3 4 ArrhythmiaRisk factorsDiabetes 3 high blood lipids excess weight Smoking excessive drug use and excessive alcohol intakePreventionHealthy eating exercise avoiding tobacco smoke limited alcohol intake 3 Overall lifestyle changesTreatmentTreating high blood pressure high blood lipids diabetes 3 MedicationAspirin beta blockers blood thinnersDeaths17 9 million 32 2015 5 The underlying mechanisms vary depending on the disease 3 It is estimated that dietary risk factors are associated with 53 of CVD deaths 6 Coronary artery disease stroke and peripheral artery disease involve atherosclerosis 3 This may be caused by high blood pressure smoking diabetes mellitus lack of exercise obesity high blood cholesterol poor diet excessive alcohol consumption 3 and poor sleep 7 8 among other things High blood pressure is estimated to account for approximately 13 of CVD deaths while tobacco accounts for 9 diabetes 6 lack of exercise 6 and obesity 5 3 Rheumatic heart disease may follow untreated strep throat 3 It is estimated that up to 90 of CVD may be preventable 9 10 Prevention of CVD involves improving risk factors through healthy eating exercise avoidance of tobacco smoke and limiting alcohol intake 3 Treating risk factors such as high blood pressure blood lipids and diabetes is also beneficial 3 Treating people who have strep throat with antibiotics can decrease the risk of rheumatic heart disease 11 The use of aspirin in people who are otherwise healthy is of unclear benefit 12 13 Cardiovascular diseases are the leading cause of death worldwide except Africa 3 Together CVD resulted in 17 9 million deaths 32 1 in 2015 up from 12 3 million 25 8 in 1990 5 4 Deaths at a given age from CVD are more common and have been increasing in much of the developing world while rates have declined in most of the developed world since the 1970s 14 15 Coronary artery disease and stroke account for 80 of CVD deaths in males and 75 of CVD deaths in females 3 Most cardiovascular disease affects older adults In the United States 11 of people between 20 and 40 have CVD while 37 between 40 and 60 71 of people between 60 and 80 and 85 of people over 80 have CVD 2 The average age of death from coronary artery disease in the developed world is around 80 while it is around 68 in the developing world 14 CVD is typically diagnosed seven to ten years earlier in men than in women 3 48 Contents 1 Types 2 Risk factors 2 1 Genetics 2 2 Age 2 3 Sex 2 4 Tobacco 2 5 Physical inactivity 2 6 Diet 2 7 Alcohol 2 8 Celiac disease 2 9 Sleep 2 10 Socioeconomic disadvantage 2 11 Air pollution 2 12 Cardiovascular risk assessment 2 13 Depression and traumatic stress 2 14 Occupational exposure 2 14 1 Non chemical risk factors 2 14 2 Chemical risk factors 2 15 Somatic mutations 2 16 Radiation therapy 3 Pathophysiology 4 Screening 5 Prevention 5 1 Diet 5 1 1 Intermittent fasting 5 2 Medication 5 3 Physical activity 5 4 Dietary supplements 6 Management 7 Epidemiology 8 Research 9 References 10 External linksTypes nbsp Disability adjusted life year for inflammatory heart diseases per 100 000 inhabitants in 2004 16 No data Less than 70 70 140 140 210 210 280 280 350 350 420 420 490 490 560 560 630 630 700 700 770 More than 770There are many cardiovascular diseases involving the blood vessels They are known as vascular diseases citation needed Coronary artery disease also known as coronary heart disease and ischemic heart disease Peripheral arterial disease disease of blood vessels that supply blood to the arms and legs Cerebrovascular disease disease of blood vessels that supply blood to the brain includes stroke Renal artery stenosis Aortic aneurysmThere are also many cardiovascular diseases that involve the heart Cardiomyopathy diseases of cardiac muscle Hypertensive heart disease diseases of the heart secondary to high blood pressure or hypertension Heart failure a clinical syndrome caused by the inability of the heart to supply sufficient blood to the tissues to meet their metabolic requirements Pulmonary heart disease a failure at the right side of the heart with respiratory system involvement Cardiac dysrhythmias abnormalities of heart rhythm Inflammatory heart disease Endocarditis inflammation of the inner layer of the heart the endocardium The structures most commonly involved are the heart valves Inflammatory cardiomegaly Myocarditis inflammation of the myocardium the muscular part of the heart caused most often by viral infection and less often by bacterial infections certain medications toxins and autoimmune disorders It is characterized in part by infiltration of the heart by lymphocyte and monocyte types of white blood cells Eosinophilic myocarditis inflammation of the myocardium caused by pathologically activated eosinophilic white blood cells This disorder differs from myocarditis in its causes and treatments Valvular heart disease Congenital heart disease heart structure malformations existing at birth Rheumatic heart disease heart muscles and valves damage due to rheumatic fever caused by Streptococcus pyogenes a group A streptococcal infection Risk factorsThere are many risk factors for heart diseases age sex tobacco use physical inactivity non alcoholic fatty liver disease excessive alcohol consumption unhealthy diet obesity genetic predisposition and family history of cardiovascular disease raised blood pressure hypertension raised blood sugar diabetes mellitus raised blood cholesterol hyperlipidemia undiagnosed celiac disease psychosocial factors poverty and low educational status air pollution and poor sleep 3 17 18 19 20 21 While the individual contribution of each risk factor varies between different communities or ethnic groups the overall contribution of these risk factors is very consistent 22 Some of these risk factors such as age sex or family history genetic predisposition are immutable however many important cardiovascular risk factors are modifiable by lifestyle change social change drug treatment for example prevention of hypertension hyperlipidemia and diabetes 23 People with obesity are at increased risk of atherosclerosis of the coronary arteries 24 Genetics Cardiovascular disease in a person s parents increases their risk by 3 fold 25 and genetics is an important risk factor for cardiovascular diseases Genetic cardiovascular disease can occur either as a consequence of single variant Mendelian or polygenic influences 26 There are more than 40 inherited cardiovascular disease that can be traced to a single disease causing DNA variant although these conditions are rare 26 Most common cardiovascular diseases are non Mendelian and are thought to be due to hundreds or thousands of genetic variants known as single nucleotide polymorphisms each associated with a small effect 27 28 Age nbsp Calcified heart of an older woman with cardiomegalyAge is the most important risk factor in developing cardiovascular or heart diseases with approximately a tripling of risk with each decade of life 29 Coronary fatty streaks can begin to form in adolescence 30 It is estimated that 82 percent of people who die of coronary heart disease are 65 and older 31 Simultaneously the risk of stroke doubles every decade after age 55 32 Multiple explanations are proposed to explain why age increases the risk of cardiovascular heart diseases One of them relates to serum cholesterol level 33 In most populations the serum total cholesterol level increases as age increases In men this increase levels off around age 45 to 50 years In women the increase continues sharply until age 60 to 65 years 33 Aging is also associated with changes in the mechanical and structural properties of the vascular wall which leads to the loss of arterial elasticity and reduced arterial compliance and may subsequently lead to coronary artery disease 34 Sex See also Cardiovascular disease in women Men are at greater risk of heart disease than pre menopausal women 29 35 Once past menopause it has been argued that a woman s risk is similar to a man s 35 although more recent data from the WHO and UN disputes this 29 If a female has diabetes she is more likely to develop heart disease than a male with diabetes 36 Women who have high blood pressure and had complications in their pregnancy have three times the risk of developing cardiovascular disease compared to women with normal blood pressure who had no complications in pregnancy 37 38 Coronary heart diseases are 2 to 5 times more common among middle aged men than women 33 In a study done by the World Health Organization sex contributes to approximately 40 of the variation in sex ratios of coronary heart disease mortality 39 Another study reports similar results finding that sex differences explains nearly half the risk associated with cardiovascular diseases 33 One of the proposed explanations for sex differences in cardiovascular diseases is hormonal difference 33 Among women estrogen is the predominant sex hormone Estrogen may have protective effects on glucose metabolism and hemostatic system and may have direct effect in improving endothelial cell function 33 The production of estrogen decreases after menopause and this may change the female lipid metabolism toward a more atherogenic form by decreasing the HDL cholesterol level while increasing LDL and total cholesterol levels 33 Among men and women there are differences in body weight height body fat distribution heart rate stroke volume and arterial compliance 34 In the very elderly age related large artery pulsatility and stiffness are more pronounced among women than men 34 This may be caused by the women s smaller body size and arterial dimensions which are independent of menopause 34 Tobacco Cigarettes are the major form of smoked tobacco 3 Risks to health from tobacco use result not only from direct consumption of tobacco but also from exposure to second hand smoke 3 Approximately 10 of cardiovascular disease is attributed to smoking 3 however people who quit smoking by age 30 have almost as low a risk of death as never smokers 40 Physical inactivity Further information Sedentary lifestyle Insufficient physical activity defined as less than 5 x 30 minutes of moderate activity per week or less than 3 x 20 minutes of vigorous activity per week is currently the fourth leading risk factor for mortality worldwide 3 In 2008 31 3 of adults aged 15 or older 28 2 men and 34 4 women were insufficiently physically active 3 The risk of ischemic heart disease and diabetes mellitus is reduced by almost a third in adults who participate in 150 minutes of moderate physical activity each week or equivalent 41 In addition physical activity assists weight loss and improves blood glucose control blood pressure lipid profile and insulin sensitivity These effects may at least in part explain its cardiovascular benefits 3 Diet Further information Saturated fat Cardiovascular disease Salt and cardiovascular disease and Lipid hypothesis High dietary intakes of saturated fat trans fats and salt and low intake of fruits vegetables and fish are linked to cardiovascular risk although whether all these associations indicate causes is disputed The World Health Organization attributes approximately 1 7 million deaths worldwide to low fruit and vegetable consumption 3 Frequent consumption of high energy foods such as processed foods that are high in fats and sugars promotes obesity and may increase cardiovascular risk 3 The amount of dietary salt consumed may also be an important determinant of blood pressure levels and overall cardiovascular risk 3 There is moderate quality evidence that reducing saturated fat intake for at least two years reduces the risk of cardiovascular disease 42 High trans fat intake has adverse effects on blood lipids and circulating inflammatory markers 43 and elimination of trans fat from diets has been widely advocated 44 45 In 2018 the World Health Organization estimated that trans fats were the cause of more than half a million deaths per year 45 There is evidence that higher consumption of sugar is associated with higher blood pressure and unfavorable blood lipids 46 and sugar intake also increases the risk of diabetes mellitus 47 High consumption of processed meats is associated with an increased risk of cardiovascular disease possibly in part due to increased dietary salt intake 19 Alcohol Further information Alcohol and cardiovascular disease The relationship between alcohol consumption and cardiovascular disease is complex and may depend on the amount of alcohol consumed 48 There is a direct relationship between high levels of drinking alcohol and cardiovascular disease 3 Drinking at low levels without episodes of heavy drinking may be associated with a reduced risk of cardiovascular disease 49 but there is evidence that associations between moderate alcohol consumption and protection from stroke are non causal 50 At the population level the health risks of drinking alcohol exceed any potential benefits 3 51 Celiac disease Untreated celiac disease can cause the development of many types of cardiovascular diseases most of which improve or resolve with a gluten free diet and intestinal healing However delays in recognition and diagnosis of celiac disease can cause irreversible heart damage 20 Sleep A lack of good sleep in amount or quality is documented as increasing cardiovascular risk in both adults and teens Recommendations suggest that Infants typically need 12 or more hours of sleep per day adolescent at least eight or nine hours and adults seven or eight About one third of adult Americans get less than the recommended seven hours of sleep per night and in a study of teenagers just 2 2 percent of those studied got enough sleep many of whom did not get good quality sleep Studies have shown that short sleepers getting less than seven hours sleep per night have a 10 percent to 30 percent higher risk of cardiovascular disease 7 52 Sleep disorders such as sleep disordered breathing and insomnia are also associated with a higher cardiometabolic risk 53 An estimated 50 to 70 million Americans have insomnia sleep apnea or other chronic sleep disorders citation needed In addition sleep research displays differences in race and class Short sleep and poor sleep tend to be more frequently reported in ethnic minorities than in whites African Americans report experiencing short durations of sleep five times more often than whites possibly as a result of social and environmental factors Black children and children living in disadvantaged neighborhoods have much higher rates of sleep apnea 8 Socioeconomic disadvantage Cardiovascular disease affects low and middle income countries even more than high income countries 54 There is relatively little information regarding social patterns of cardiovascular disease within low and middle income countries 54 but within high income countries low income and low educational status are consistently associated with greater risk of cardiovascular disease 55 Policies that have resulted in increased socio economic inequalities have been associated with greater subsequent socio economic differences in cardiovascular disease 54 implying a cause and effect relationship Psychosocial factors environmental exposures health behaviours and health care access and quality contribute to socio economic differentials in cardiovascular disease 56 The Commission on Social Determinants of Health recommended that more equal distributions of power wealth education housing environmental factors nutrition and health care were needed to address inequalities in cardiovascular disease and non communicable diseases 57 Air pollution Particulate matter has been studied for its short and long term exposure effects on cardiovascular disease Currently airborne particles under 2 5 micrometers in diameter PM2 5 are the major focus in which gradients are used to determine CVD risk Overall long term PM exposure increased rate of atherosclerosis and inflammation In regards to short term exposure 2 hours every 25 mg m3 of PM2 5 resulted in a 48 increase of CVD mortality risk 58 In addition after only 5 days of exposure a rise in systolic 2 8 mmHg and diastolic 2 7 mmHg blood pressure occurred for every 10 5 mg m3 of PM2 5 58 Other research has implicated PM2 5 in irregular heart rhythm reduced heart rate variability decreased vagal tone and most notably heart failure 58 59 PM2 5 is also linked to carotid artery thickening and increased risk of acute myocardial infarction 58 59 Cardiovascular risk assessment Existing cardiovascular disease or a previous cardiovascular event such as a heart attack or stroke is the strongest predictor of a future cardiovascular event 60 Age sex smoking blood pressure blood lipids and diabetes are important predictors of future cardiovascular disease in people who are not known to have cardiovascular disease 61 These measures and sometimes others may be combined into composite risk scores to estimate an individual s future risk of cardiovascular disease 60 Numerous risk scores exist although their respective merits are debated 62 Other diagnostic tests and biomarkers remain under evaluation but currently these lack clear cut evidence to support their routine use They include family history coronary artery calcification score high sensitivity C reactive protein hs CRP ankle brachial pressure index lipoprotein subclasses and particle concentration lipoprotein a apolipoproteins A I and B fibrinogen white blood cell count homocysteine N terminal pro B type natriuretic peptide NT proBNP and markers of kidney function 63 64 High blood phosphorus is also linked to an increased risk 65 Depression and traumatic stress There is evidence that mental health problems in particular depression and traumatic stress is linked to cardiovascular diseases Whereas mental health problems are known to be associated with risk factors for cardiovascular diseases such as smoking poor diet and a sedentary lifestyle these factors alone do not explain the increased risk of cardiovascular diseases seen in depression stress and anxiety 66 Moreover posttraumatic stress disorder is independently associated with increased risk for incident coronary heart disease even after adjusting for depression and other covariates 67 Occupational exposure Main article Occupational cardiovascular disease Little is known about the relationship between work and cardiovascular disease but links have been established between certain toxins extreme heat and cold exposure to tobacco smoke and mental health concerns such as stress and depression 68 Non chemical risk factors A 2015 SBU report looking at non chemical factors found an association for those 69 with mentally stressful work with a lack of control over their working situation with an effort reward imbalance 69 who experience low social support at work who experience injustice or experience insufficient opportunities for personal development or those who experience job insecurity 69 those who work night schedules or have long working weeks 69 those who are exposed to noise 69 Specifically the risk of stroke was also increased by exposure to ionizing radiation 69 Hypertension develops more often in those who experience job strain and who have shift work 69 Differences between women and men in risk are small however men risk having and dying of heart attacks or stroke twice as often as women during working life 69 Chemical risk factors A 2017 SBU report found evidence that workplace exposure to silica dust engine exhaust or welding fumes is associated with heart disease 70 Associations also exist for exposure to arsenic benzopyrenes lead dynamite carbon disulphide carbon monoxide metalworking fluids and occupational exposure to tobacco smoke 70 Working with the electrolytic production of aluminium or the production of paper when the sulphate pulping process is used is associated with heart disease 70 An association was also found between heart disease and exposure to compounds which are no longer permitted in certain work environments such as phenoxy acids containing TCDD dioxin or asbestos 70 Workplace exposure to silica dust or asbestos is also associated with pulmonary heart disease There is evidence that workplace exposure to lead carbon disulphide phenoxyacids containing TCDD as well as working in an environment where aluminum is being electrolytically produced is associated with stroke 70 Somatic mutations As of 2017 evidence suggests that certain leukemia associated mutations in blood cells may also lead to increased risk of cardiovascular disease Several large scale research projects looking at human genetic data have found a robust link between the presence of these mutations a condition known as clonal hematopoiesis and cardiovascular disease related incidents and mortality 71 Radiation therapy Radiation treatments RT for cancer can increase the risk of heart disease and death as observed in breast cancer therapy 72 Therapeutic radiation increases the risk of a subsequent heart attack or stroke by 1 5 to 4 times 73 the increase depends on the dose strength volume and location Use of concomitant chemotherapy e g anthracyclines is an aggravating risk factor 74 The occurrence rate of RT induced cardiovascular disease is estimated between 10 and 30 74 Side effects from radiation therapy for cardiovascular diseases have been termed radiation induced heart disease or radiation induced cardiovascular disease 75 76 Symptoms are dose dependent and include cardiomyopathy myocardial fibrosis valvular heart disease coronary artery disease heart arrhythmia and peripheral artery disease Radiation induced fibrosis vascular cell damage and oxidative stress can lead to these and other late side effect symptoms 75 Pathophysiology nbsp Density Dependent Colour Scanning Electron Micrograph SEM DDC SEM of cardiovascular calcification showing in orange calcium phosphate spherical particles denser material and in green the extracellular matrix less dense material 77 Population based studies show that atherosclerosis the major precursor of cardiovascular disease begins in childhood The Pathobiological Determinants of Atherosclerosis in Youth PDAY study demonstrated that intimal lesions appear in all the aortas and more than half of the right coronary arteries of youths aged 7 9 years 78 Obesity and diabetes mellitus are linked to cardiovascular disease 79 as are a history of chronic kidney disease and hypercholesterolaemia 80 In fact cardiovascular disease is the most life threatening of the diabetic complications and diabetics are two to four fold more likely to die of cardiovascular related causes than nondiabetics 81 82 83 ScreeningScreening ECGs either at rest or with exercise are not recommended in those without symptoms who are at low risk 84 This includes those who are young without risk factors 85 In those at higher risk the evidence for screening with ECGs is inconclusive 86 Additionally echocardiography myocardial perfusion imaging and cardiac stress testing is not recommended in those at low risk who do not have symptoms 87 Some biomarkers may add to conventional cardiovascular risk factors in predicting the risk of future cardiovascular disease however the value of some biomarkers is questionable 88 89 Ankle brachial index ABI high sensitivity C reactive protein hsCRP and coronary artery calcium are also of unclear benefit in those without symptoms as of 2018 90 The NIH recommends lipid testing in children beginning at the age of 2 if there is a family history of heart disease or lipid problems 91 It is hoped that early testing will improve lifestyle factors in those at risk such as diet and exercise 92 Screening and selection for primary prevention interventions has traditionally been done through absolute risk using a variety of scores ex Framingham or Reynolds risk scores 93 This stratification has separated people who receive the lifestyle interventions generally lower and intermediate risk from the medication higher risk The number and variety of risk scores available for use has multiplied but their efficacy according to a 2016 review was unclear due to lack of external validation or impact analysis 94 Risk stratification models often lack sensitivity for population groups and do not account for the large number of negative events among the intermediate and low risk groups 93 As a result future preventative screening appears to shift toward applying prevention according to randomized trial results of each intervention rather than large scale risk assessment PreventionUp to 90 of cardiovascular disease may be preventable if established risk factors are avoided 9 95 Currently practised measures to prevent cardiovascular disease include Maintaining a healthy diet such as the Mediterranean diet a vegetarian vegan or another plant based diet 96 97 98 99 Replacing saturated fat with healthier choices Clinical trials show that replacing saturated fat with polyunsaturated vegetable oil reduced CVD by 30 Prospective observational studies show that in many populations lower intake of saturated fat coupled with higher intake of polyunsaturated and monounsaturated fat is associated with lower rates of CVD 100 Decrease body fat if overweight or obese 101 The effect of weight loss is often difficult to distinguish from dietary change and evidence on weight reducing diets is limited 102 In observational studies of people with severe obesity weight loss following bariatric surgery is associated with a 46 reduction in cardiovascular risk 103 Limit alcohol consumption to the recommended daily limits 96 People who moderately consume alcoholic drinks have a 25 30 lower risk of cardiovascular disease 104 105 However people who are genetically predisposed to consume less alcohol have lower rates of cardiovascular disease 106 suggesting that alcohol itself may not be protective Excessive alcohol intake increases the risk of cardiovascular disease 107 105 and consumption of alcohol is associated with increased risk of a cardiovascular event in the day following consumption 105 Decrease non HDL cholesterol 108 109 Statin treatment reduces cardiovascular mortality by about 31 110 Stopping smoking and avoidance of second hand smoke 96 Stopping smoking reduces risk by about 35 111 At least 150 minutes 2 hours and 30 minutes of moderate exercise per week 112 113 Lower blood pressure if elevated A 10 mmHg reduction in blood pressure reduces risk by about 20 114 Lowering blood pressure appears to be effective even at normal blood pressure ranges 115 116 117 Decrease psychosocial stress 118 This measure may be complicated by imprecise definitions of what constitute psychosocial interventions 119 Mental stress induced myocardial ischemia is associated with an increased risk of heart problems in those with previous heart disease 120 Severe emotional and physical stress leads to a form of heart dysfunction known as Takotsubo syndrome in some people 121 Stress however plays a relatively minor role in hypertension 122 Specific relaxation therapies are of unclear benefit 123 124 Not enough sleep also raises the risk of high blood pressure Adults need about 7 9 hours of sleep Sleep apnea is also a major risk as it causes breathing to stop briefly which can put stress on the body which can raise the risk of heart disease 125 126 Most guidelines recommend combining preventive strategies There is some evidence that interventions aiming to reduce more than one cardiovascular risk factor may have beneficial effects on blood pressure body mass index and waist circumference however evidence was limited and the authors were unable to draw firm conclusions on the effects on cardiovascular events and mortality 127 There is additional evidence to suggest that providing people with a cardiovascular disease risk score may reduce risk factors by a small amount compared to usual care 128 However there was some uncertainty as to whether providing these scores had any effect on cardiovascular disease events It is unclear whether or not dental care in those with periodontitis affects their risk of cardiovascular disease 129 Diet See also Lipid hypothesis Saturated fat and cardiovascular disease and Salt and cardiovascular disease A diet high in fruits and vegetables decreases the risk of cardiovascular disease and death 130 A 2021 review found that plant based diets can provide a risk reduction for CVD if a healthy plant based diet is consumed Unhealthy plant based diets do not provide benefits over diets including meat 97 A similar meta analysis and systematic review also looked into dietary patterns and found that diets lower in animal foods and unhealthy plant foods and higher in healthy plant foods are beneficial for CVD prevention 98 A 2018 meta analysis of observational studies concluded that In most countries a vegan diet is associated with a more favourable cardio metabolic profile compared to an omnivorous diet 99 Evidence suggests that the Mediterranean diet may improve cardiovascular outcomes 131 There is also evidence that a Mediterranean diet may be more effective than a low fat diet in bringing about long term changes to cardiovascular risk factors e g lower cholesterol level and blood pressure 132 The DASH diet high in nuts fish fruits and vegetables and low in sweets red meat and fat has been shown to reduce blood pressure 133 lower total and low density lipoprotein cholesterol 134 and improve metabolic syndrome 135 but the long term benefits have been questioned 136 A high fiber diet is associated with lower risks of cardiovascular disease 137 Worldwide dietary guidelines recommend a reduction in saturated fat 138 and although the role of dietary fat in cardiovascular disease is complex and controversial there is a long standing consensus that replacing saturated fat with unsaturated fat in the diet is sound medical advice 139 Total fat intake has not been found to be associated with cardiovascular risk 140 141 A 2020 systematic review found moderate quality evidence that reducing saturated fat intake for at least 2 years caused a reduction in cardiovascular events 142 A 2015 meta analysis of observational studies however did not find a convincing association between saturated fat intake and cardiovascular disease 143 Variation in what is used as a substitute for saturated fat may explain some differences in findings 139 The benefit from replacement with polyunsaturated fats appears greatest 144 while replacement of saturated fats with carbohydrates does not appear to have a beneficial effect 144 A diet high in trans fatty acids is associated with higher rates of cardiovascular disease 145 and in 2015 the Food and Drug Administration FDA determined that there was no longer a consensus among qualified experts that partially hydrogenated oils PHOs which are the primary dietary source of industrially produced trans fatty acids IP TFA are generally recognized as safe GRAS for any use in human food 146 There is conflicting evidence concerning whether dietary supplements of omega 3 fatty acids a type of polyunsaturated fat in oily fish added to diet improve cardiovascular risk 147 148 The benefits of recommending a low salt diet in people with high or normal blood pressure are not clear 149 In those with heart failure after one study was left out the rest of the trials show a trend to benefit 150 151 Another review of dietary salt concluded that there is strong evidence that high dietary salt intake increases blood pressure and worsens hypertension and that it increases the number of cardiovascular disease events both as a result of the increased blood pressure and probably through other mechanisms 152 153 Moderate evidence was found that high salt intake increases cardiovascular mortality and some evidence was found for an increase in overall mortality strokes and left ventricular hypertrophy 152 Intermittent fasting Overall the current body of scientific evidence is uncertain on whether intermittent fasting could prevent cardiovascular disease 154 Intermittent fasting may help people lose more weight than regular eating patterns but was not different from energy restriction diets 154 Medication Blood pressure medication reduces cardiovascular disease in people at risk 114 irrespective of age 155 the baseline level of cardiovascular risk 156 or baseline blood pressure 157 The commonly used drug regimens have similar efficacy in reducing the risk of all major cardiovascular events although there may be differences between drugs in their ability to prevent specific outcomes 158 Larger reductions in blood pressure produce larger reductions in risk 158 and most people with high blood pressure require more than one drug to achieve adequate reduction in blood pressure 159 Adherence to medications is often poor and while mobile phone text messaging has been tried to improve adherence there is insufficient evidence that it alters secondary prevention of cardiovascular disease 160 Statins are effective in preventing further cardiovascular disease in people with a history of cardiovascular disease 161 As the event rate is higher in men than in women the decrease in events is more easily seen in men than women 161 In those at risk but without a history of cardiovascular disease primary prevention statins decrease the risk of death and combined fatal and non fatal cardiovascular disease 162 The benefit however is small 163 A United States guideline recommends statins in those who have a 12 or greater risk of cardiovascular disease over the next ten years 164 Niacin fibrates and CETP Inhibitors while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins 165 Fibrates lower the risk of cardiovascular and coronary events but there is no evidence to suggest that they reduce all cause mortality 166 Anti diabetic medication may reduce cardiovascular risk in people with Type 2 diabetes although evidence is not conclusive 167 A meta analysis in 2009 including 27 049 participants and 2 370 major vascular events showed a 15 relative risk reduction in cardiovascular disease with more intensive glucose lowering over an average follow up period of 4 4 years but an increased risk of major hypoglycemia 168 Aspirin has been found to be of only modest benefit in those at low risk of heart disease as the risk of serious bleeding is almost equal to the protection against cardiovascular problems 169 In those at very low risk including those over the age of 70 it is not recommended 170 171 The United States Preventive Services Task Force recommends against use of aspirin for prevention in women less than 55 and men less than 45 years old however it is recommended for some older people 172 The use of vasoactive agents for people with pulmonary hypertension with left heart disease or hypoxemic lung diseases may cause harm and unnecessary expense 173 Antibiotics for secondary prevention of coronary heart diseaseAntibiotics may help patients with coronary disease to reduce the risk of heart attacks and strokes 174 However evidence in 2021 suggests that antibiotics for secondary prevention of coronary heart disease are harmful with increased mortality and occurrence of stroke 174 the use of antibiotics is not supported for preventing secondary coronary heart disease Physical activity Exercise based cardiac rehabilitation following a heart attack reduces the risk of death from cardiovascular disease and leads to less hospitalizations 175 There have been few high quality studies of the benefits of exercise training in people with increased cardiovascular risk but no history of cardiovascular disease 176 A systematic review estimated that inactivity is responsible for 6 of the burden of disease from coronary heart disease worldwide 177 The authors estimated that 121 000 deaths from coronary heart disease could have been averted in Europe in 2008 if people had not been physically inactive Low quality evidence from a limited number of studies suggest that yoga has beneficial effects on blood pressure and cholesterol 178 Tentative evidence suggests that home based exercise programs may be more efficient at improving exercise adherence 179 Dietary supplements While a healthy diet is beneficial the effect of antioxidant supplementation vitamin E vitamin C etc or vitamins has not been shown to protect against cardiovascular disease and in some cases may possibly result in harm 180 181 182 183 Mineral supplements have also not been found to be useful 184 Niacin a type of vitamin B3 may be an exception with a modest decrease in the risk of cardiovascular events in those at high risk 185 186 Magnesium supplementation lowers high blood pressure in a dose dependent manner 187 Magnesium therapy is recommended for people with ventricular arrhythmia associated with torsades de pointes who present with long QT syndrome and for the treatment of people with digoxin intoxication induced arrhythmias 188 There is no evidence that omega 3 fatty acid supplementation is beneficial 189 A 2022 review found that some dietary supplements including micronutrients may reduce risk factors for cardiovascular disease 190 ManagementCardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions 3 Influenza may make heart attacks and strokes more likely and therefore influenza vaccination may decrease the chance of cardiovascular events and death in people with heart disease 191 Proper CVD management necessitates a focus on MI and stroke cases due to their combined high mortality rate keeping in mind the cost effectiveness of any intervention especially in developing countries with low or middle income levels 93 Regarding MI strategies using aspirin atenolol streptokinase or tissue plasminogen activator have been compared for quality adjusted life year QALY in regions of low and middle income The costs for a single QALY for aspirin and atenolol were less than US 25 streptokinase was about 680 and t PA was 16 000 192 Aspirin ACE inhibitors beta blockers and statins used together for secondary CVD prevention in the same regions showed single QALY costs of 350 192 There are also surgical or procedural interventions that can save someone s life or prolong it For heart valve problems a person could have surgery to replace the valve For arrhythmias a pacemaker can be put in place to help reduce abnormal heart rhythms and for a heart attack there are multiple options two of these are a coronary angioplasty and a coronary artery bypass surgery 193 There is probably no additional benefit in terms of mortality and serious adverse events when blood pressure targets were lowered to 135 85 mmHg from 140 to 160 90 to 100 mmHg 194 Epidemiology nbsp Cardiovascular diseases deaths per million persons in 2012 318 925 926 1 148 1 149 1 294 1 295 1 449 1 450 1 802 1 803 2 098 2 099 2 624 2 625 3 203 3 204 5 271 5 272 10233 nbsp Disability adjusted life year for cardiovascular diseases per 100 000 inhabitants in 2004 16 no data lt 900 900 1650 1650 2300 2300 3000 3000 3700 3700 4400 4400 5100 5100 5800 5800 6500 6500 7200 7200 7900 gt 7900Cardiovascular diseases are the leading cause of death worldwide and in all regions except Africa 3 In 2008 30 of all global death was attributed to cardiovascular diseases Death caused by cardiovascular diseases are also higher in low and middle income countries as over 80 of all global deaths caused by cardiovascular diseases occurred in those countries It is also estimated that by 2030 over 23 million people will die from cardiovascular diseases each year It is estimated that 60 of the world s cardiovascular disease burden will occur in the South Asian subcontinent despite only accounting for 20 of the world s population This may be secondary to a combination of genetic predisposition and environmental factors Organizations such as the Indian Heart Association are working with the World Heart Federation to raise awareness about this issue 195 ResearchSee also Heart on a chip and Vessel on a chip There is evidence that cardiovascular disease existed in pre history 196 and research into cardiovascular disease dates from at least the 18th century 197 The causes prevention and or treatment of all forms of cardiovascular disease remain active fields of biomedical research with hundreds of scientific studies being published on a weekly basis Recent areas of research include the link between inflammation and atherosclerosis 198 the potential for novel therapeutic interventions 199 and the genetics of coronary heart disease 200 References Heart disease Mayo Clinic 2022 08 25 a b Go AS Mozaffarian D Roger VL Benjamin EJ Berry JD Borden WB et al January 2013 Heart disease and stroke statistics 2013 update a report from the American Heart Association Circulation 127 1 e6 e245 doi 10 1161 cir 0b013e31828124ad PMC 5408511 PMID 23239837 a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad Shanthi M Pekka P Norrving B 2011 Global Atlas on Cardiovascular Disease Prevention and Control PDF World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization pp 3 18 ISBN 978 92 4 156437 3 Archived PDF from the original on 2014 08 17 a b c Naghavi M Wang H Lozano R Davis A Liang X Zhou M et al GBD 2013 Mortality and Causes of Death Collaborators January 2015 Global regional and national age sex specific all cause and cause specific mortality for 240 causes of death 1990 2013 a systematic analysis for the Global Burden of Disease Study 2013 Lancet 385 9963 117 71 doi 10 1016 S0140 6736 14 61682 2 PMC 4340604 PMID 25530442 a b Wang H Naghavi M Allen C Barber RM Bhutta ZA Carter A et al GBD 2015 Mortality and Causes of Death Collaborators October 2016 Global regional and national life expectancy all cause mortality and cause specific mortality for 249 causes of death 1980 2015 a systematic analysis for the Global Burden of Disease Study 2015 Lancet 388 10053 1459 1544 doi 10 1016 S0140 6736 16 31012 1 PMC 5388903 PMID 27733281 Petersen Kristina S Kris Etherton Penny M 2021 11 28 Diet quality assessment and the relationship between diet quality and cardiovascular disease risk Nutrients 13 12 4305 doi 10 3390 nu13124305 ISSN 2072 6643 PMC 8706326 PMID 34959857 a b Jackson CL Redline S Emmons KM March 2015 Sleep as a potential fundamental contributor to disparities in cardiovascular health Annual Review of Public Health 36 1 417 40 doi 10 1146 annurev publhealth 031914 122838 PMC 4736723 PMID 25785893 a b Wang R Dong Y Weng J Kontos EZ Chervin RD Rosen CL et al January 2017 Associations among Neighborhood Race and Sleep Apnea Severity in Children A Six City Analysis Annals of the American Thoracic Society 14 1 76 84 doi 10 1513 AnnalsATS 201609 662OC PMC 5291481 PMID 27768852 a b McGill HC McMahan CA Gidding SS March 2008 Preventing heart disease in the 21st century implications of the Pathobiological Determinants of Atherosclerosis in Youth PDAY study Circulation 117 9 1216 27 doi 10 1161 CIRCULATIONAHA 107 717033 PMID 18316498 O Donnell MJ Chin SL Rangarajan S Xavier D Liu L Zhang H et al August 2016 Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries INTERSTROKE a case control study Lancet 388 10046 761 75 doi 10 1016 S0140 6736 16 30506 2 PMID 27431356 S2CID 39752176 Spinks Anneliese Glasziou Paul P Del Mar Chris B 2021 12 09 Antibiotics for treatment of sore throat in children and adults The Cochrane Database of Systematic Reviews 2021 12 CD000023 doi 10 1002 14651858 CD000023 pub5 ISSN 1469 493X PMC 8655103 PMID 34881426 Sutcliffe P Connock M Gurung T Freeman K Johnson S Ngianga Bakwin K et al 2013 Aspirin in primary prevention of cardiovascular disease and cancer a systematic review of the balance of evidence from reviews of randomized trials PLOS ONE 8 12 e81970 Bibcode 2013PLoSO 881970S doi 10 1371 journal pone 0081970 PMC 3855368 PMID 24339983 Sutcliffe P Connock M Gurung T Freeman K Johnson S Kandala NB et al September 2013 Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer a systematic review and overview of reviews Health Technology Assessment 17 43 1 253 doi 10 3310 hta17430 PMC 4781046 PMID 24074752 a b Institute of Medicine of the National Academies 2010 Epidemiology of Cardiovascular Disease In Fuster V Kelly BB eds Promoting cardiovascular health in the developing world a critical challenge to achieve global health Washington DC National Academies Press ISBN 978 0 309 14774 3 Archived from the original on 2017 09 08 Moran AE Forouzanfar MH Roth GA Mensah GA Ezzati M Murray CJ Naghavi M April 2014 Temporal trends in ischemic heart disease mortality in 21 world regions 1980 to 2010 the Global Burden of Disease 2010 study Circulation 129 14 1483 92 doi 10 1161 circulationaha 113 004042 PMC 4181359 PMID 24573352 a b WHO Disease and injury country estimates World Health Organization 2009 Archived from the original on 2009 11 11 Fuster V Kelly BB eds 2010 Promoting Cardiovascular Health in the Developing World A Critical Challenge to Achieve Global Health Washington DC National Academies Press ISBN 978 0 309 14774 3 Finks SW Airee A Chow SL Macaulay TE Moranville MP Rogers KC Trujillo TC April 2012 Key articles of dietary interventions that influence cardiovascular mortality Pharmacotherapy 32 4 e54 87 doi 10 1002 j 1875 9114 2011 01087 x PMID 22392596 S2CID 36437057 a b Micha R Michas G Mozaffarian D December 2012 Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes an updated review of the evidence Current Atherosclerosis Reports 14 6 515 24 doi 10 1007 s11883 012 0282 8 PMC 3483430 PMID 23001745 a b Ciaccio EJ Lewis SK Biviano AB Iyer V Garan H Green PH August 2017 Cardiovascular involvement in celiac disease World Journal of Cardiology Review 9 8 652 666 doi 10 4330 wjc v9 i8 652 PMC 5583538 PMID 28932354 Duell PB Welty FK Miller M Chait A Hammond G Ahmad Z Cohen DE Horton JD Pressman GS Toth PP American Heart Association Council on Atherosclerosis Thrombosis and Vascular Biology Council on Hypertension Council on the Kidney in Cardiovascular Disease Council on Lifestyle and Cardiometabolic Health Council on Peripheral Vascular Disease April 2022 Nonalcoholic Fatty Liver Disease and Cardiovascular Risk A Scientific Statement From the American Heart Association Arteriosclerosis Thrombosis and Vascular Biology 42 6 e168 e185 doi 10 1161 ATV 0000000000000153 PMID 35418240 S2CID 248155592 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Yusuf S Hawken S Ounpuu S Dans T Avezum A Lanas F et al 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries the INTERHEART study case control study Lancet 364 9438 937 52 doi 10 1016 S0140 6736 04 17018 9 hdl 10983 21615 PMID 15364185 S2CID 30811593 McPhee S 2012 Current medical diagnosis amp treatment New York McGraw Hill Medical pp 430 ISBN 978 0 07 176372 1 Eckel RH November 1997 Obesity and heart disease a statement for healthcare professionals from the Nutrition Committee American Heart Association Circulation 96 9 3248 50 doi 10 1161 01 CIR 96 9 3248 PMID 9386201 Kathiresan S Srivastava D March 2012 Genetics of human cardiovascular disease Cell 148 6 1242 57 doi 10 1016 j cell 2012 03 001 PMC 3319439 PMID 22424232 a b Semsarian Christopher Ingles Jodie Ross Samantha Barratt Dunwoodie Sally L Bagnall Richard D Kovacic Jason C 2021 05 25 Precision Medicine in Cardiovascular Disease Genetics and Impact on Phenotypes JACC Focus Seminar 1 5 Journal of the American College of Cardiology 77 20 2517 2530 doi 10 1016 j jacc 2020 12 071 ISSN 0735 1097 PMID 34016265 S2CID 235073575 Nikpay M Goel A Won HH Hall LM Willenborg C Kanoni S et al October 2015 A comprehensive 1 000 Genomes based genome wide association meta analysis of coronary artery disease PDF Nature Genetics 47 10 1121 1130 doi 10 1038 ng 3396 PMC 4589895 PMID 26343387 via University of Dundee MacRae CA Vasan RS June 2016 The Future of Genetics and Genomics Closing the Phenotype Gap in Precision Medicine Circulation 133 25 2634 9 doi 10 1161 CIRCULATIONAHA 116 022547 PMC 6188655 PMID 27324359 a b c Finegold JA Asaria P Francis DP September 2013 Mortality from ischaemic heart disease by country region and age statistics from World Health Organisation and United Nations International Journal of Cardiology 168 2 934 45 doi 10 1016 j ijcard 2012 10 046 PMC 3819990 PMID 23218570 D Adamo E Guardamagna O Chiarelli F Bartuli A Liccardo D Ferrari F Nobili V 2015 Atherogenic dyslipidemia and cardiovascular risk factors in obese children International Journal of Endocrinology 2015 912047 doi 10 1155 2015 912047 PMC 4309297 PMID 25663838 Understand Your Risk of Heart Attack American Heart Association http www heart org HEARTORG Conditions HeartAttack UnderstandYourRiskofHeartAttack Understand Your Risk of Heart Attack UCM 002040 Article jsp Mackay Judith Mensah George Mendis Shanthi Greenland Kurt January 2004 The Atlas of Heart Disease and Stroke World Health Organization and U S Centers for Disease Control and Prevention hdl 10665 43007 ISBN 978 92 4 156276 8 a b c d e f g Jousilahti P Vartiainen E Tuomilehto J Puska P March 1999 Sex age cardiovascular risk factors and coronary heart disease a prospective follow up study of 14 786 middle aged men and women in Finland Circulation 99 9 1165 72 doi 10 1161 01 cir 99 9 1165 PMID 10069784 a b c d Jani B Rajkumar C June 2006 Ageing and vascular ageing Postgraduate Medical Journal 82 968 357 62 doi 10 1136 pgmj 2005 036053 PMC 2563742 PMID 16754702 a b Cardiovascular disease risk factors World Heart Federation 2012 Archived from the original on 2012 05 10 Diabetes raises women s risk of heart disease more than for men NPR org May 22 2014 Archived from the original on May 23 2014 Retrieved May 23 2014 Pregnancy complications increase the risk of heart attacks and stroke in women with high blood pressure NIHR Evidence Plain English summary National Institute for Health and Care Research 2023 11 21 doi 10 3310 nihrevidence 60660 Al Khalaf S Chappell LC Khashan AS McCarthy FP O Reilly EJ July 2023 Association Between Chronic Hypertension and the Risk of 12 Cardiovascular Diseases Among Parous Women The Role of Adverse Pregnancy Outcomes Hypertension 80 7 1427 1438 doi 10 1161 HYPERTENSIONAHA 122 20628 PMID 37170819 Jackson R Chambles L Higgins M Kuulasmaa K Wijnberg L Williams D WHO MONICA Project and ARIC Study Sex difference in ischaemic heart disease mortality and risk factors in 46 communities an ecologic analysis Cardiovasc Risk Factors 1999 7 43 54 Doll R Peto R Boreham J Sutherland I June 2004 Mortality in relation to smoking 50 years observations on male British doctors BMJ 328 7455 1519 doi 10 1136 bmj 38142 554479 AE PMC 437139 PMID 15213107 World Health Organization UNAIDS 2007 Prevention of Cardiovascular Disease World Health Organization pp 3 ISBN 978 92 4 154726 0 Archived from the original on 27 April 2016 Hooper L Martin N Jimoh OF Kirk C Foster E Abdelhamid AS August 2020 Reduction in saturated fat intake for cardiovascular disease The Cochrane Database of Systematic Reviews 2020 8 CD011737 doi 10 1002 14651858 CD011737 pub3 PMC 8092457 PMID 32827219 Booker CS Mann JI July 2008 Trans fatty acids and cardiovascular health translation of the evidence base Nutrition Metabolism and Cardiovascular Diseases 18 6 448 56 doi 10 1016 j numecd 2008 02 005 PMID 18468872 Remig V Franklin B Margolis S Kostas G Nece T Street JC April 2010 Trans fats in America a review of their use consumption health implications and regulation Journal of the American Dietetic Association 110 4 585 92 doi 10 1016 j jada 2009 12 024 hdl 2097 6377 PMID 20338284 a b WHO plan to eliminate industrially produced trans fatty acids from global food supply Press release World Health Organization 14 May 2018 Te Morenga LA Howatson AJ Jones RM Mann J July 2014 Dietary sugars and cardiometabolic risk systematic review and meta analyses of randomized controlled trials of the effects on blood pressure and lipids The American Journal of Clinical Nutrition 100 1 65 79 doi 10 3945 ajcn 113 081521 PMID 24808490 Howard BV Wylie Rosett J Jul 23 2002 Sugar and cardiovascular disease A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition Physical Activity and Metabolism of the American Heart Association Circulation 106 4 523 7 doi 10 1161 01 cir 0000019552 77778 04 PMID 12135957 S2CID 1589727 Bell S Daskalopoulou M Rapsomaniki E George J Britton A Bobak M et al March 2017 Association between clinically recorded alcohol consumption and initial presentation of 12 cardiovascular diseases population based cohort study using linked health records BMJ 356 j909 doi 10 1136 bmj j909 PMC 5594422 PMID 28331015 Mukamal KJ Chen CM Rao SR Breslow RA March 2010 Alcohol consumption and cardiovascular mortality among U S adults 1987 to 2002 Journal of the American College of Cardiology 55 13 1328 35 doi 10 1016 j jacc 2009 10 056 PMC 3865979 PMID 20338493 Millwood IY Walters RG Mei XW Guo Y Yang L Bian Z et al May 2019 Conventional and genetic evidence on alcohol and vascular disease aetiology a prospective study of 500 000 men and women in China Lancet 393 10183 1831 1842 doi 10 1016 S0140 6736 18 31772 0 PMC 6497989 PMID 30955975 World Health Organization 2011 Global Status Report on Alcohol and Health World Health Organization ISBN 978 92 4 156415 1 Archived from the original on 2016 05 07 Cespedes Feliciano EM Quante M Rifas Shiman SL Redline S Oken E Taveras EM July 2018 Objective Sleep Characteristics and Cardiometabolic Health in Young Adolescents Pediatrics 142 1 e20174085 doi 10 1542 peds 2017 4085 PMC 6260972 PMID 29907703 Retrieved 28 June 2021 St Onge MP Grandner MA Brown D Conroy MB Jean Louis G Coons M Bhatt DL November 2016 Sleep Duration and Quality Impact on Lifestyle Behaviors and Cardiometabolic Health A Scientific Statement From the American Heart Association Circulation Review 134 18 e367 e386 doi 10 1161 CIR 0000000000000444 PMC 5567876 PMID 27647451 a b c Di Cesare M Khang YH Asaria P Blakely T Cowan MJ Farzadfar F et al February 2013 Inequalities in non communicable diseases and effective responses Lancet 381 9866 585 97 doi 10 1016 S0140 6736 12 61851 0 hdl 10906 80012 PMID 23410608 S2CID 41892834 Mackenbach JP Cavelaars AE Kunst AE Groenhof F July 2000 Socioeconomic inequalities in cardiovascular disease mortality an international study European Heart Journal 21 14 1141 51 doi 10 1053 euhj 1999 1990 PMID 10924297 S2CID 8747779 Clark AM DesMeules M Luo W Duncan AS Wielgosz A November 2009 Socioeconomic status and cardiovascular disease risks and implications for care Nature Reviews Cardiology 6 11 712 22 doi 10 1038 nrcardio 2009 163 PMID 19770848 S2CID 21835944 World Health Organization 2008 Closing the Gap in a Generation Health Equity Through Action on the Social Determinants of Health Commission on Social Determinants of Health Final Report World Health Organization pp 26 ISBN 978 92 4 156370 3 Archived from the original on 2016 05 01 a b c d Franchini M Mannucci PM March 2012 Air pollution and cardiovascular disease Thrombosis Research 129 3 230 4 doi 10 1016 j thromres 2011 10 030 PMID 22113148 a b Sun Q Hong X Wold LE June 2010 Cardiovascular effects of ambient particulate air pollution exposure Circulation 121 25 2755 65 doi 10 1161 CIRCULATIONAHA 109 893461 PMC 2924678 PMID 20585020 a b Tunstall Pedoe H March 2011 Cardiovascular Risk and Risk Scores ASSIGN Framingham QRISK and others how to choose Heart 97 6 442 4 doi 10 1136 hrt 2010 214858 PMID 21339319 S2CID 6420111 World Health Organization 2007 Prevention of Cardiovascular Disease Guidelines for Assessment and Management of Cardiovascular Risk World Health Organization ISBN 978 92 4 154717 8 Archived from the original on 2016 05 06 van Staa TP Gulliford M Ng ES Goldacre B Smeeth L 2014 Prediction of cardiovascular risk using Framingham ASSIGN and QRISK2 how well do they predict individual rather than population risk PLOS ONE 9 10 e106455 Bibcode 2014PLoSO 9j6455V doi 10 1371 journal pone 0106455 PMC 4182667 PMID 25271417 nbsp Hlatky MA Greenland P Arnett DK Ballantyne CM Criqui MH Elkind MS et al May 2009 Criteria for evaluation of novel markers of cardiovascular risk a scientific statement from the American Heart Association Circulation 119 17 2408 16 doi 10 1161 CIRCULATIONAHA 109 192278 PMC 2956982 PMID 19364974 Eckel RH Cornier MA August 2014 Update on the NCEP ATP III emerging cardiometabolic risk factors BMC Medicine 12 1 115 doi 10 1186 1741 7015 12 115 PMC 4283079 PMID 25154373 nbsp Bai W Li J Liu J October 2016 Serum phosphorus cardiovascular and all cause mortality in the general population A meta analysis Clinica Chimica Acta International Journal of Clinical Chemistry 461 76 82 doi 10 1016 j cca 2016 07 020 PMID 27475981 Cohen BE Edmondson D Kronish IM November 2015 State of the Art Review Depression Stress Anxiety and Cardiovascular Disease American Journal of Hypertension 28 11 1295 302 doi 10 1093 ajh hpv047 PMC 4612342 PMID 25911639 Edmondson D Kronish IM Shaffer JA Falzon L Burg MM November 2013 Posttraumatic stress disorder and risk for coronary heart disease a meta analytic review American Heart Journal 166 5 806 14 doi 10 1016 j ahj 2013 07 031 PMC 3815706 PMID 24176435 NIOSH Program Portfolio Cancer Reproductive and Cardiovascular Diseases Program Description CDC Archived from the original on 2016 05 15 Retrieved 2016 06 07 a b c d e f g h Swedish Agency for Health Technology Assessment and Assessment of Social Services SBU 2015 08 26 Occupational Exposures and Cardiovascular Disease www sbu se Archived from the original on 2017 06 14 Retrieved 2017 06 01 a b c d e Swedish Agency for Health Technology Assessment and Assessment of Social Services SBU Occupational health and safety chemical exposure www sbu se Archived from the original on 2017 06 06 Retrieved 2017 06 01 Jan M Ebert BL Jaiswal S January 2017 Clonal hematopoiesis Seminars in Hematology 54 1 43 50 doi 10 1053 j seminhematol 2016 10 002 PMC 8045769 PMID 28088988 Taylor CW Nisbet A McGale P Darby SC December 2007 Cardiac exposures in breast cancer radiotherapy 1950s 1990s International Journal of Radiation Oncology Biology Physics 69 5 1484 95 doi 10 1016 j ijrobp 2007 05 034 PMID 18035211 Weintraub NL Jones WK Manka D March 2010 Understanding radiation induced vascular disease Journal of the American College of Cardiology 55 12 1237 1239 doi 10 1016 j jacc 2009 11 053 PMC 3807611 PMID 20298931 a b Benveniste Marcelo F Gomez Daniel Carter Brett W Betancourt Cuellar Sonia L Shroff Girish S Benveniste Ana Paula Odisio Erika G Marom Edith M March 7 2019 Recognizing Radiation Therapy related Complications in the Chest RadioGraphics 39 2 353 doi 10 1148 rg 2019180061 PMID 30844346 S2CID 73477338 Retrieved 24 August 2023 a b Klee NS McCarthy CG Martinez Quinones P Webb RC November 2017 Out of the frying pan and into the fire damage associated molecular patterns and cardiovascular toxicity following cancer therapy Therapeutic Advances in Cardiovascular Disease 11 11 297 317 doi 10 1177 1753944717729141 PMC 5933669 PMID 28911261 Belzile Dugas E Eisenberg MJ September 2021 Radiation Induced Cardiovascular Disease Review of an Underrecognized Pathology J Am Heart Assoc 10 18 e021686 doi 10 1161 JAHA 121 021686 PMC 8649542 PMID 34482706 Bertazzo S Gentleman E Cloyd KL Chester AH Yacoub MH Stevens MM June 2013 Nano analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification Nature Materials 12 6 576 83 Bibcode 2013NatMa 12 576B doi 10 1038 nmat3627 PMC 5833942 PMID 23603848 Vanhecke TE Miller WM Franklin BA Weber JE McCullough PA October 2006 Awareness knowledge and perception of heart disease among adolescents European Journal of Cardiovascular Prevention and Rehabilitation 13 5 718 23 doi 10 1097 01 hjr 0000214611 91490 5e PMID 17001210 S2CID 36312234 Highlander P Shaw GP February 2010 Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics Therapeutic Advances in Cardiovascular Disease 4 1 43 54 doi 10 1177 1753944709354305 PMID 19965897 S2CID 23913203 NPS Medicinewise 1 March 2011 NPS Prescribing Practice Review 53 Managing lipids Archived from the original on 19 March 2011 Retrieved 1 August 2011 Kvan E Pettersen KI Sandvik L Reikvam A October 2007 High mortality in diabetic patients with acute myocardial infarction cardiovascular co morbidities contribute most to the high risk International Journal of Cardiology 121 2 184 8 doi 10 1016 j ijcard 2006 11 003 PMID 17184858 Norhammar A Malmberg K Diderholm E Lagerqvist B Lindahl B Ryden L Wallentin L February 2004 Diabetes mellitus the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization Journal of the American College of Cardiology 43 4 585 91 doi 10 1016 j jacc 2003 08 050 PMID 14975468 DECODE European Diabetes Epidemiology Group August 1999 Glucose tolerance and mortality comparison of WHO and American Diabetes Association diagnostic criteria The DECODE study group European Diabetes Epidemiology Group Diabetes Epidemiology Collaborative analysis Of Diagnostic criteria in Europe Lancet 354 9179 617 21 doi 10 1016 S0140 6736 98 12131 1 PMID 10466661 S2CID 54227479 Curry SJ Krist AH Owens DK Barry MJ Caughey AB Davidson KW et al June 2018 Screening for Cardiovascular Disease Risk With Electrocardiography US Preventive Services Task Force Recommendation Statement JAMA 319 22 2308 2314 doi 10 1001 jama 2018 6848 PMID 29896632 Maron BJ Friedman RA Kligfield P Levine BD Viskin S Chaitman BR et al October 2014 Assessment of the 12 lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people 12 25 Years of Age a scientific statement from the American Heart Association and the American College of Cardiology Circulation 130 15 1303 34 doi 10 1161 CIR 0000000000000025 PMID 25223981 Moyer VA October 2012 Screening for coronary heart disease with electrocardiography U S Preventive Services Task Force recommendation statement Annals of Internal Medicine 157 7 512 8 doi 10 7326 0003 4819 157 7 201210020 00514 PMID 22847227 Chou R March 2015 Cardiac screening with electrocardiography stress echocardiography or myocardial perfusion imaging advice for high value care from the American College of Physicians Annals of Internal Medicine 162 6 438 47 doi 10 7326 M14 1225 PMID 25775317 S2CID 207538193 Wang TJ Gona P Larson MG Tofler GH Levy D Newton Cheh C et al December 2006 Multiple biomarkers for the prediction of first major cardiovascular events and death The New England Journal of Medicine 355 25 2631 9 doi 10 1056 NEJMoa055373 PMID 17182988 S2CID 196411135 Spence JD November 2006 Technology Insight ultrasound measurement of carotid plaque patient management genetic research and therapy evaluation Nature Clinical Practice Neurology 2 11 611 9 doi 10 1038 ncpneuro0324 PMID 17057748 S2CID 26077254 Curry SJ Krist AH Owens DK Barry MJ Caughey AB Davidson KW et al July 2018 Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors US Preventive Services Task Force Recommendation Statement JAMA 320 3 272 280 doi 10 1001 jama 2018 8359 PMID 29998297 Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children Adolescents December 2011 Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents summary report Pediatrics 128 Supplement 5 S213 56 doi 10 1542 peds 2009 2107C PMC 4536582 PMID 22084329 Saenger AK August 2012 Universal lipid screening in children and adolescents a baby step toward primordial prevention Clinical Chemistry 58 8 1179 81 doi 10 1373 clinchem 2012 182287 PMID 22510399 a b c Mann DL Zipes DP Libby P Bonow RO Braunwald E 2014 Braunwald s heart disease a textbook of cardiovascular medicine Tenth ed Philadelphia ISBN 978 1 4557 5133 4 OCLC 890409638 a href Template Cite book html title Template Cite book cite book a CS1 maint location missing publisher link Damen JA Hooft L Schuit E Debray TP Collins GS Tzoulaki I et al May 2016 Prediction models for cardiovascular disease risk in the general population systematic review BMJ 353 i2416 doi 10 1136 bmj i2416 PMC 4868251 PMID 27184143 McNeal CJ Dajani T Wilson D Cassidy Bushrow AE Dickerson JB Ory M January 2010 Hypercholesterolemia in youth opportunities and obstacles to prevent premature atherosclerotic cardiovascular disease Current Atherosclerosis Reports 12 1 20 8 doi 10 1007 s11883 009 0072 0 PMID 20425267 S2CID 37833889 a b c Heart Attack Prevention NHS Direct 28 November 2019 a b Quek Jingxuan Lim Grace Lim Wen Hui Ng Cheng Han So Wei Zheng Toh Jonathan Pan Xin Hui Chin Yip Han Muthiah Mark D Chan Siew Pang Foo Roger S Y 2021 11 05 The Association of Plant Based Diet With Cardiovascular Disease and Mortality A Meta Analysis and Systematic Review of Prospect Cohort Studies Frontiers in Cardiovascular Medicine 8 756810 doi 10 3389 fcvm 2021 756810 ISSN 2297 055X PMC 8604150 PMID 34805312 a b Gan Zuo Hua Cheong Huey Chiat Tu Yu Kang Kuo Po Hsiu 2021 11 05 Association between Plant Based Dietary Patterns and Risk of Cardiovascular Disease A Systematic Review and Meta Analysis of Prospective Cohort Studies Nutrients 13 11 3952 doi 10 3390 nu13113952 ISSN 2072 6643 PMC 8624676 PMID 34836208 a b Benatar Jocelyne R Stewart Ralph A H 2018 Cardiometabolic risk factors in vegans A meta analysis of observational studies PLOS ONE 13 12 e0209086 Bibcode 2018PLoSO 1309086B doi 10 1371 journal pone 0209086 ISSN 1932 6203 PMC 6301673 PMID 30571724 Frank M Sacks Alice H Lichtenstein Jason H Y Wu Lawrence J Appel Mark A Creager Penny M Kris Etherton Michael Miller Eric B Rimm Lawrence L Rudel Jennifer G Robinson Neil J Stone and Linda V Van Horn Dietary Fats and Cardiovascular Disease A Presidential Advisory From the American Heart Association 15 Jun 2017 https doi org 10 1161 CIR 0000000000000510Circulation 2017 136 e1 e23 https www ahajournals org doi full 10 1161 CIR 0000000000000510 McTigue KM Hess R Ziouras J September 2006 Obesity in older adults a systematic review of the evidence for diagnosis and treatment Obesity 14 9 1485 97 doi 10 1038 oby 2006 171 PMID 17030958 S2CID 45241607 Semlitsch T Krenn C Jeitler K Berghold A Horvath K Siebenhofer A February 2021 Long term effects of weight reducing diets in people with hypertension The Cochrane Database of Systematic Reviews 2021 2 CD008274 doi 10 1002 14651858 CD008274 pub4 PMC 8093137 PMID 33555049 Kwok CS Pradhan A Khan MA Anderson SG Keavney BD Myint PK et al April 2014 Bariatric surgery and its impact on cardiovascular disease and mortality a systematic review and meta analysis International Journal of Cardiology 173 1 20 8 doi 10 1016 j ijcard 2014 02 026 hdl 2164 3181 PMID 24636546 Ronksley PE Brien SE Turner BJ Mukamal KJ Ghali WA February 2011 Association of alcohol consumption with selected cardiovascular disease outcomes a systematic review and meta analysis BMJ 342 d671 doi 10 1136 bmj d671 PMC 3043109 PMID 21343207 a b c Mostofsky E Chahal HS Mukamal KJ Rimm EB Mittleman MA March 2016 Alcohol and Immediate Risk of Cardiovascular Events A Systematic Review and Dose Response Meta Analysis Circulation 133 10 979 87 doi 10 1161 CIRCULATIONAHA 115 019743 PMC 4783255 PMID 26936862 Holmes MV Dale CE Zuccolo L Silverwood RJ Guo Y Ye Z et al July 2014 Association between alcohol and cardiovascular disease Mendelian randomisation analysis based on individual participant data BMJ 349 g4164 doi 10 1136 bmj g4164 PMC 4091648 PMID 25011450 Klatsky AL May 2009 Alcohol and cardiovascular diseases Expert Review of Cardiovascular Therapy 7 5 499 506 doi 10 1586 erc 09 22 PMID 19419257 S2CID 23782870 McMahan CA Gidding SS Malcom GT Tracy RE Strong JP McGill HC October 2006 Pathobiological determinants of atherosclerosis in youth risk scores are associated with early and advanced atherosclerosis Pediatrics 118 4 1447 55 doi 10 1542 peds 2006 0970 PMID 17015535 S2CID 37741456 Raitakari OT Ronnemaa T Jarvisalo MJ Kaitosaari T Volanen I Kallio K et al December 2005 Endothelial function in healthy 11 year old children after dietary intervention with onset in infancy the Special Turku Coronary Risk Factor Intervention Project for children STRIP Circulation 112 24 3786 94 doi 10 1161 CIRCULATIONAHA 105 583195 PMID 16330680 Chou R Dana T Blazina I Daeges M Jeanne TL November 2016 Statins for Prevention of Cardiovascular Disease in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force JAMA 316 19 2008 2024 doi 10 1001 jama 2015 15629 PMID 27838722 Critchley J Capewell S 2004 01 01 Critchley JA ed Smoking cessation for the secondary prevention of coronary heart disease The Cochrane Database of Systematic Reviews 1 CD003041 doi 10 1002 14651858 CD003041 pub2 PMID 14974003 Retracted see doi 10 1002 14651858 cd003041 pub3 Chapter 4 Active Adults health gov Archived from the original on 2017 03 13 Physical activity guidelines for adults NHS Choices 2018 04 26 Archived from the original on 2017 02 19 a b Ettehad D Emdin CA Kiran A Anderson SG Callender T Emberson J et al March 2016 Blood pressure lowering for prevention of cardiovascular disease and death a systematic review and meta analysis Lancet 387 10022 957 967 doi 10 1016 S0140 6736 15 01225 8 PMID 26724178 Many more people could benefit from blood pressure lowering medication medicalxpress com Retrieved 14 June 2021 expert reaction to study looking at pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure Science Media Centre Retrieved 14 June 2021 Adler A Agodoa L Algra A Asselbergs FW Beckett NS Berge E et al May 2021 Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure an individual participant level data meta analysis Lancet 397 10285 1625 1636 doi 10 1016 S0140 6736 21 00590 0 PMC 8102467 PMID 33933205 nbsp Available under CC BY 4 0 Linden W Stossel C Maurice J April 1996 Psychosocial interventions for patients with coronary artery disease a meta analysis Archives of Internal Medicine 156 7 745 52 doi 10 1001 archinte 1996 00440070065008 PMID 8615707 S2CID 45312858 Thompson DR Ski CF December 2013 Psychosocial interventions in cardiovascular disease what are they PDF European Journal of Preventive Cardiology 20 6 916 7 doi 10 1177 2047487313494031 PMID 24169589 S2CID 35497445 Wei J Rooks C Ramadan R Shah AJ Bremner JD Quyyumi AA et al July 2014 Meta analysis of mental stress induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease The American Journal of Cardiology 114 2 187 92 doi 10 1016 j amjcard 2014 04 022 PMC 4126399 PMID 24856319 Pelliccia F Greco C Vitale C Rosano G Gaudio C Kaski JC August 2014 Takotsubo syndrome stress cardiomyopathy an intriguing clinical condition in search of its identity The American Journal of Medicine 127 8 699 704 doi 10 1016 j amjmed 2014 04 004 hdl 11573 562721 PMID 24754972 Marshall IJ Wolfe CD McKevitt C July 2012 Lay perspectives on hypertension and drug adherence systematic review of qualitative research BMJ 345 e3953 doi 10 1136 bmj e3953 PMC 3392078 PMID 22777025 Dickinson HO Mason JM Nicolson DJ Campbell F Beyer FR Cook JV et al February 2006 Lifestyle interventions to reduce raised blood pressure a systematic review of randomized controlled trials Journal of Hypertension 24 2 215 33 doi 10 1097 01 hjh 0000199800 72563 26 PMID 16508562 S2CID 9125890 Abbott RA Whear R Rodgers LR Bethel A Thompson Coon J Kuyken W et al May 2014 Effectiveness of mindfulness based stress reduction and mindfulness based cognitive therapy in vascular disease A systematic review and meta analysis of randomised controlled trials Journal of Psychosomatic Research 76 5 341 51 doi 10 1016 j jpsychores 2014 02 012 PMID 24745774 U S National Library of Medicine 2021 March 24 Heart Disease Prevention MedlinePlus https medlineplus gov howtopreventheartdisease html U S Department of Health and Human Services n d Cardiovascular Disease National Center for Complementary and Integrative Health https www nccih nih gov health cardiovascular disease Uthman OA Hartley L Rees K Taylor F Ebrahim S Clarke A August 2015 Multiple risk factor interventions for primary prevention of cardiovascular disease in low and middle income countries PDF The Cochrane Database of Systematic Reviews 2015 8 CD011163 doi 10 1002 14651858 CD011163 pub2 PMC 6999125 PMID 26272648 Karmali KN Persell SD Perel P Lloyd Jones DM Berendsen MA Huffman MD March 2017 Risk scoring for the primary prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 3 6 CD006887 doi 10 1002 14651858 CD006887 pub4 PMC 6464686 PMID 28290160 Ye Zelin Cao Yubin Miao Cheng Liu Wei Dong Li Lv Zongkai Iheozor Ejiofor Zipporah Li Chunjie 2022 10 04 Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis The Cochrane Database of Systematic Reviews 2022 10 CD009197 doi 10 1002 14651858 CD009197 pub5 ISSN 1469 493X PMC 9531722 PMID 36194420 Wang X Ouyang Y Liu J Zhu M Zhao G Bao W Hu FB July 2014 Fruit and vegetable consumption and mortality from all causes cardiovascular disease and cancer systematic review and dose response meta analysis of prospective cohort studies BMJ 349 g4490 doi 10 1136 bmj g4490 PMC 4115152 PMID 25073782 Walker C Reamy BV April 2009 Diets for cardiovascular disease prevention what is the evidence American Family Physician 79 7 571 8 PMID 19378874 Nordmann AJ Suter Zimmermann K Bucher HC Shai I Tuttle KR Estruch R Briel M September 2011 Meta analysis comparing Mediterranean to low fat diets for modification of cardiovascular risk factors The American Journal of Medicine 124 9 841 51 e2 doi 10 1016 j amjmed 2011 04 024 PMID 21854893 Archived from the original on 2013 12 20 Sacks FM Svetkey LP Vollmer WM Appel LJ Bray GA Harsha D et al January 2001 Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension DASH diet DASH Sodium Collaborative Research Group The New England Journal of Medicine 344 1 3 10 doi 10 1056 NEJM200101043440101 PMID 11136953 Obarzanek E Sacks FM Vollmer WM Bray GA Miller ER Lin PH et al July 2001 Effects on blood lipids of a blood pressure lowering diet the Dietary Approaches to Stop Hypertension DASH Trial The American Journal of Clinical Nutrition 74 1 80 9 doi 10 1093 ajcn 74 1 80 PMID 11451721 Azadbakht L Mirmiran P Esmaillzadeh A Azizi T Azizi F December 2005 Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome Diabetes Care 28 12 2823 31 doi 10 2337 diacare 28 12 2823 PMID 16306540 Logan AG March 2007 DASH Diet time for a critical appraisal American Journal of Hypertension 20 3 223 4 doi 10 1016 j amjhyper 2006 10 006 PMID 17324730 Hajishafiee M Saneei P Benisi Kohansal S Esmaillzadeh A July 2016 Cereal Fibre Intake and Risk of Mortality From All Causes CVD Cancer and Inflammatory Diseases A Systematic Review and Meta Analysis of Prospective Cohort Studies The British Journal of Nutrition 116 2 343 52 doi 10 1017 S0007114516001938 PMID 27193606 Ramsden CE Zamora D Leelarthaepin B Majchrzak Hong SF Faurot KR Suchindran CM et al February 2013 Use of dietary linoleic acid for secondary prevention of coronary heart disease and death evaluation of recovered data from the Sydney Diet Heart Study and updated meta analysis BMJ 346 e8707 doi 10 1136 bmj e8707 PMC 4688426 PMID 23386268 a b Lichtenstein AH November 2019 Dietary Fat and Cardiovascular Disease Ebb and Flow Over the Last Half Century Advances in Nutrition 10 Suppl 4 S332 S339 doi 10 1093 advances nmz024 PMC 6855944 PMID 31728492 Food and Agriculture Organization of the United Nations 2010 Fats and fatty acids in human nutrition report of an expert consultation 10 14 November 2008 Geneva Rome Food and Agriculture Organization of the United Nations ISBN 978 92 5 106733 8 OCLC 712123395 Archived from the original on 2014 12 28 Willett WC July 2012 Dietary fats and coronary heart disease Journal of Internal Medicine 272 1 13 24 doi 10 1111 j 1365 2796 2012 02553 x PMID 22583051 S2CID 43493760 Hooper Lee Martin Nicole Jimoh Oluseyi F Kirk Christian Foster Eve Abdelhamid Asmaa S 21 August 2020 Reduction in saturated fat intake for cardiovascular disease The Cochrane Database of Systematic Reviews 2020 8 CD011737 doi 10 1002 14651858 CD011737 pub3 ISSN 1469 493X PMC 8092457 PMID 32827219 de Souza RJ Mente A Maroleanu A Cozma AI Ha V Kishibe T et al August 2015 Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality cardiovascular disease and type 2 diabetes systematic review and meta analysis of observational studies BMJ 351 h3978 h3978 doi 10 1136 bmj h3978 PMC 4532752 PMID 26268692 a b Sacks FM Lichtenstein AH Wu JH Appel LJ Creager MA Kris Etherton PM et al July 2017 Dietary Fats and Cardiovascular Disease A Presidential Advisory From the American Heart Association Circulation 136 3 e1 e23 doi 10 1161 CIR 0000000000000510 PMID 28620111 S2CID 367602 Chowdhury R Warnakula S Kunutsor S Crowe F Ward HA Johnson L et al March 2014 Association of dietary circulating and supplement fatty acids with coronary risk a systematic review and meta analysis Annals of Internal Medicine 160 6 398 406 doi 10 7326 M13 1788 PMID 24723079 S2CID 52013596 Food Drug Administration HHS May 2018 Final Determination Regarding Partially Hydrogenated Oils Notification declaratory order extension of compliance date Federal Register 83 98 23358 9 PMID 30019869 Abdelhamid AS Brown TJ Brainard JS Biswas P Thorpe GC Moore HJ et al February 2020 Omega 3 fatty acids for the primary and secondary prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 2020 3 CD003177 doi 10 1002 14651858 CD003177 pub5 PMC 7049091 PMID 32114706 Aung T Halsey J Kromhout D Gerstein HC Marchioli R Tavazzi L et al March 2018 Associations of Omega 3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta analysis of 10 Trials Involving 77 917 Individuals JAMA Cardiology 3 3 225 234 doi 10 1001 jamacardio 2017 5205 PMC 5885893 PMID 29387889 Adler AJ Taylor F Martin N Gottlieb S Taylor RS Ebrahim S December 2014 Reduced dietary salt for the prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 2014 12 CD009217 doi 10 1002 14651858 CD009217 pub3 PMC 6483405 PMID 25519688 He FJ MacGregor GA July 2011 Salt reduction lowers cardiovascular risk meta analysis of outcome trials PDF Lancet 378 9789 380 2 doi 10 1016 S0140 6736 11 61174 4 PMID 21803192 S2CID 43795786 Archived from the original PDF on 2013 12 20 Retrieved 2013 08 23 Paterna S Gaspare P Fasullo S Sarullo FM Di Pasquale P February 2008 Normal sodium diet compared with low sodium diet in compensated congestive heart failure is sodium an old enemy or a new friend PDF Clinical Science 114 3 221 30 doi 10 1042 CS20070193 PMID 17688420 S2CID 2248777 a b Bochud M Marques Vidal P Burnier M Paccaud F 2012 Dietary Salt Intake and Cardiovascular Disease Summarizing the Evidence Public Health Reviews 33 2 530 52 doi 10 1007 BF03391649 Archived from the original on 2013 12 21 Cook NR Cutler JA Obarzanek E Buring JE Rexrode KM Kumanyika SK et al April 2007 Long term effects of dietary sodium reduction on cardiovascular disease outcomes observational follow up of the trials of hypertension prevention TOHP BMJ 334 7599 885 8 doi 10 1136 bmj 39147 604896 55 PMC 1857760 PMID 17449506 a b Allaf M Elghazaly H Mohamed OG Fareen MF Zaman S Salmasi AM et al Cochrane Heart Group January 2021 Intermittent fasting for the prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 1 3 CD013496 doi 10 1002 14651858 CD013496 pub2 PMC 8092432 PMID 33512717 Turnbull F Neal B Ninomiya T Algert C Arima H Barzi F et al May 2008 Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults meta analysis of randomised trials BMJ 336 7653 1121 3 doi 10 1136 bmj 39548 738368 BE PMC 2386598 PMID 18480116 Blood Pressure Lowering Treatment Trialists Collaboration August 2014 Blood pressure lowering treatment based on cardiovascular risk a meta analysis of individual patient data Lancet 384 9943 591 598 doi 10 1016 S0140 6736 14 61212 5 PMID 25131978 S2CID 19951800 Czernichow S Zanchetti A Turnbull F Barzi F Ninomiya T Kengne AP et al January 2011 The effects of blood pressure reduction and of different blood pressure lowering regimens on major cardiovascular events according to baseline blood pressure meta analysis of randomized trials Journal of Hypertension 29 1 4 16 doi 10 1097 HJH 0b013e32834000be PMID 20881867 S2CID 10374187 a b Turnbull F November 2003 Effects of different blood pressure lowering regimens on major cardiovascular events results of prospectively designed overviews of randomised trials Lancet Submitted manuscript 362 9395 1527 35 doi 10 1016 s0140 6736 03 14739 3 PMID 14615107 S2CID 10730075 Go AS Bauman MA Coleman King SM Fonarow GC Lawrence W Williams KA Sanchez E April 2014 An effective approach to high blood pressure control a science advisory from the American Heart Association the American College of Cardiology and the Centers for Disease Control and Prevention Hypertension 63 4 878 85 doi 10 1161 HYP 0000000000000003 PMC 10280688 PMID 24243703 Adler AJ Martin N Mariani J Tajer CD Owolabi OO Free C et al Cochrane Heart Group April 2017 Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 2017 4 CD011851 doi 10 1002 14651858 CD011851 pub2 PMC 6478182 PMID 28455948 a b Gutierrez J Ramirez G Rundek T Sacco RL June 2012 Statin therapy in the prevention of recurrent cardiovascular events a sex based meta analysis Archives of Internal Medicine 172 12 909 19 doi 10 1001 archinternmed 2012 2145 PMID 22732744 Taylor F Huffman MD Macedo AF Moore TH Burke M Davey Smith G et al January 2013 Statins for the primary prevention of cardiovascular disease PDF The Cochrane Database of Systematic Reviews 1 1 CD004816 doi 10 1002 14651858 CD004816 pub5 PMC 6481400 PMID 23440795 Statins in primary cardiovascular prevention Prescrire International 27 195 183 July August 2018 Retrieved 4 August 2018 Downs JR O Malley PG August 2015 Management of dyslipidemia for cardiovascular disease risk reduction synopsis of the 2014 U S Department of Veterans Affairs and U S Department of Defense clinical practice guideline Annals of Internal Medicine 163 4 291 7 doi 10 7326 m15 0840 PMID 26099117 Keene D Price C Shun Shin MJ Francis DP July 2014 Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin fibrates and CETP inhibitors meta analysis of randomised controlled trials including 117 411 patients BMJ 349 g4379 doi 10 1136 bmj g4379 PMC 4103514 PMID 25038074 Jakob T Nordmann AJ Schandelmaier S Ferreira Gonzalez I Briel M et al Cochrane Heart Group November 2016 Fibrates for primary prevention of cardiovascular disease events The Cochrane Database of Systematic Reviews 11 3 CD009753 doi 10 1002 14651858 CD009753 pub2 PMC 6464497 PMID 27849333 Holman RR Sourij H Califf RM June 2014 Cardiovascular outcome trials of glucose lowering drugs or strategies in type 2 diabetes Lancet 383 9933 2008 17 doi 10 1016 s0140 6736 14 60794 7 PMID 24910232 S2CID 5064731 Turnbull FM Abraira C Anderson RJ Byington RP Chalmers JP Duckworth WC et al November 2009 Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 11 2288 98 doi 10 1007 s00125 009 1470 0 PMID 19655124 Berger JS Lala A Krantz MJ Baker GS Hiatt WR July 2011 Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease a meta analysis of randomized trials American Heart Journal 162 1 115 24 e2 doi 10 1016 j ahj 2011 04 006 PMID 21742097 Final Recommendation Statement Aspirin for the Prevention of Cardiovascular Disease Preventive Medication March 2009 Archived from the original on 10 January 2015 Retrieved 15 January 2015 Arnett DK Blumenthal RS Albert MA Buroker AB Goldberger ZD Hahn EJ et al March 2019 2019 ACC AHA Guideline on the Primary Prevention of Cardiovascular Disease A Report of the American College of Cardiology American Heart Association Task Force on Clinical Practice Guidelines Journal of the American College of Cardiology 74 10 e177 e232 doi 10 1016 j jacc 2019 03 010 PMC 7685565 PMID 30894318 US Preventive Services Task Force March 2009 Aspirin for the prevention of cardiovascular disease U S Preventive Services Task Force recommendation statement Annals of Internal Medicine 150 6 396 404 doi 10 7326 0003 4819 150 6 200903170 00008 PMID 19293072 American College of Chest Physicians American Thoracic Society September 2013 Five Things Physicians and Patients Should Question Choosing Wisely an initiative of the ABIM Foundation American College of Chest Physicians and American Thoracic Society archived from the original on 3 November 2013 retrieved 6 January 2013 a b Sethi NJ Safi S Korang SK Hrobjartsson A Skoog M Gluud C Jakobsen JC et al Cochrane Heart Group February 2021 Antibiotics for secondary prevention of coronary heart disease The Cochrane Database of Systematic Reviews 2 5 CD003610 doi 10 1002 14651858 CD003610 pub4 PMC 8094925 PMID 33704780 Dibben Grace Faulkner James Oldridge Neil Rees Karen Thompson David R Zwisler Ann Dorthe Taylor Rod S 6 November 2021 Exercise based cardiac rehabilitation for coronary heart disease The Cochrane Database of Systematic Reviews 2021 11 CD001800 doi 10 1002 14651858 CD001800 pub4 ISSN 1469 493X PMC 8571912 PMID 34741536 Seron P Lanas F Pardo Hernandez H Bonfill Cosp X August 2014 Exercise for people with high cardiovascular risk The Cochrane Database of Systematic Reviews 2014 8 CD009387 doi 10 1002 14651858 CD009387 pub2 PMC 6669260 PMID 25120097 Lee IM Shiroma EJ Lobelo F Puska P Blair SN Katzmarzyk PT July 2012 Effect of physical inactivity on major non communicable diseases worldwide an analysis of burden of disease and life expectancy Lancet 380 9838 219 29 doi 10 1016 S0140 6736 12 61031 9 PMC 3645500 PMID 22818936 Hartley L Dyakova M Holmes J Clarke A Lee MS Ernst E Rees K May 2014 Yoga for the primary prevention of cardiovascular disease PDF The Cochrane Database of Systematic Reviews 2014 5 CD010072 doi 10 1002 14651858 CD010072 pub2 PMC 10075056 PMID 24825181 Ashworth NL Chad KE Harrison EL Reeder BA Marshall SC January 2005 Home versus center based physical activity programs in older adults The Cochrane Database of Systematic Reviews 2005 1 CD004017 doi 10 1002 14651858 cd004017 pub2 PMC 6464851 PMID 15674925 Al Khudairy L Flowers N Wheelhouse R Ghannam O Hartley L Stranges S Rees K March 2017 Vitamin C supplementation for the primary prevention of cardiovascular disease The Cochrane Database of Systematic Reviews 2017 3 CD011114 doi 10 1002 14651858 CD011114 pub2 PMC 6464316 PMID 28301692 Bhupathiraju SN Tucker KL August 2011 Coronary heart disease prevention nutrients foods and dietary patterns Clinica Chimica Acta International Journal of Clinical Chemistry 412 17 18 1493 514 doi 10 1016 j cca 2011 04 038 PMC 5945285 PMID 21575619 Myung SK Ju W Cho B Oh SW Park SM Koo BK Park BJ January 2013 Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease systematic review and meta analysis of randomised controlled trials BMJ 346 f10 doi 10 1136 bmj f10 PMC 3548618 PMID 23335472 Kim J Choi J Kwon SY McEvoy JW Blaha MJ Blumenthal RS et al July 2018 Association of Multivitamin and Mineral Supplementation and Risk of Cardiovascular Disease A Systematic Review and Meta Analysis Circulation Cardiovascular Quality and Outcomes 11 7 e004224 doi 10 1161 CIRCOUTCOMES 117 004224 PMID 29991644 S2CID 51615818 Fortmann SP Burda BU Senger CA Lin JS Whitlock EP December 2013 Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer An updated systematic evidence review for the U S Preventive Services Task Force Annals of Internal Medicine 159 12 824 34 doi 10 7326 0003 4819 159 12 201312170 00729 PMID 24217421 Bruckert E Labreuche J Amarenco P June 2010 Meta analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2 353 61 doi 10 1016 j atherosclerosis 2009 12 023 PMID 20079494 Lavigne PM Karas RH January 2013 The current state of niacin in cardiovascular disease prevention a systematic review and meta regression Journal of the American College of Cardiology 61 4 440 446 doi 10 1016 j jacc 2012 10 030 PMID 23265337 Jee SH Miller ER Guallar E Singh VK Appel LJ Klag MJ August 2002 The effect of magnesium supplementation on blood pressure a meta analysis of randomized clinical trials American Journal of Hypertension 15 8 691 6 doi 10 1016 S0895 7061 02 02964 3 PMID 12160191 Zipes DP Camm AJ Borggrefe M Buxton AE Chaitman B Fromer M et al September 2006 ACC AHA ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death a report of the American College of Cardiology American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 10 e385 484 doi 10 1161 CIRCULATIONAHA 106 178233 PMID 16935995 Kwak SM Myung SK Lee YJ Seo HG May 2012 Efficacy of omega 3 fatty acid supplements eicosapentaenoic acid and docosahexaenoic acid in the secondary prevention of cardiovascular disease a meta analysis of randomized double blind placebo controlled trials Archives of Internal Medicine 172 9 686 94 doi 10 1001 archinternmed 2012 262 PMID 22493407 An Peng Wan Sitong Luo Yongting et al 13 December 2022 Micronutrient supplementation to reduce cardiovascular risk Journal of the American College of Cardiology 80 24 2269 2285 doi 10 1016 j jacc 2022 09 048 ISSN 0735 1097 PMID 36480969 S2CID 254343574 Clar C Oseni Z Flowers N Keshtkar Jahromi M Rees K May 2015 Influenza vaccines for preventing cardiovascular disease The Cochrane Database of Systematic Reviews 2015 5 CD005050 doi 10 1002 14651858 CD005050 pub3 PMC 8511741 PMID 25940444 S2CID 205176857 a b Zipes DP Libby P Bonow RO Mann DL Tomaselli GF 2018 Braunwald s Heart Disease E Book A Textbook of Cardiovascular Medicine Elsevier Health Sciences p 15 ISBN 9780323555937 What is Cardiovascular Disease www heart org 31 May 2017 Saiz Luis Carlos Gorricho Javier Garjon Javier Celaya Mª Concepcion Erviti Juan Leache Leire 2022 11 18 Blood pressure targets for the treatment of people with hypertension and cardiovascular disease The Cochrane Database of Systematic Reviews 2022 11 CD010315 doi 10 1002 14651858 CD010315 pub5 ISSN 1469 493X PMC 9673465 PMID 36398903 Roo S Cardiac Disease Among South Asians A Silent Epidemic Indian Heart Association Archived from the original on 2015 05 18 Retrieved 2018 12 31 Thompson RC Allam AH Lombardi GP Wann LS Sutherland ML Sutherland JD et al April 2013 Atherosclerosis across 4000 years of human history the Horus study of four ancient populations Lancet 381 9873 1211 22 doi 10 1016 s0140 6736 13 60598 x PMID 23489753 S2CID 16928278 Alberti FB 2013 05 01 John Hunter s Heart The Bulletin of the Royal College of Surgeons of England 95 5 168 69 doi 10 1308 003588413X13643054409261 ISSN 1473 6357 Ruparelia N Chai JT Fisher EA Choudhury RP March 2017 Inflammatory processes in cardiovascular disease a route to targeted therapies Nature Reviews Cardiology 14 3 133 144 doi 10 1038 nrcardio 2016 185 PMC 5525550 PMID 27905474 Tang WH Hazen SL January 2017 Atherosclerosis in 2016 Advances in new therapeutic targets for atherosclerosis Nature Reviews Cardiology 14 2 71 72 doi 10 1038 nrcardio 2016 216 PMC 5880294 PMID 28094270 Swerdlow DI Humphries SE February 2017 Genetics of CHD in 2016 Common and rare genetic variants and risk of CHD Nature Reviews Cardiology 14 2 73 74 doi 10 1038 nrcardio 2016 209 PMID 28054577 S2CID 13738641 External linksWHO fact sheet on cardiovascular diseases 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Heart Disease MedicineNet Slides photos descriptions Risk calculator Retrieved from https en wikipedia org w index php title Cardiovascular disease amp oldid 1187012336, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.